

The role of nutritional vitamin D in CKD-MBD in children and adults with CKD, on dialysis and after kidney transplantation – a European consensus statement

Hanne Skou Jørgensen^{1,2} (0000-0002-0881-2615), Marc Vervloet³, Etienne Cavalier⁴, Justine Bacchetta⁵, Martin H de Borst⁶, Jordi Bover⁷, Mario Cozzolino⁸, Ana Carina Ferreira⁹, Ditte Hansen^{10,11} (0000-0003-4929-7901), Markus Herrmann¹², Renate de Jongh¹³, Sandro Mazzaferro¹⁴, Mandy Wan¹⁵, Rukshana Shroff¹⁶ (0000-0001-8501-1072), Pieter Evenepoel¹⁷ (0000-0002-0797-4321)

On behalf of the European Renal Osteodystrophy (EUROD) initiative under the Chronic Kidney Disease – Mineral and Bone Disorder working group of the European Renal Association (ERA) and the Dialysis and Chronic Kidney Disease – Mineral and Bone disorder working groups of the European Society of Paediatric Nephrology (ESPN)



¹Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

²Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark

³Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands

⁴Department of Clinical Chemistry, CIRM, University of Liege, CHU de Liège, Liège, Belgium

⁵Department of Pediatric Nephrology, Reference Center for Rare Diseases of Calcium and Phosphate, INSERM1033 Research Unit, Hospices Civils de Lyon, Université Lyon 1, Lyon, France

⁶Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.


- ⁷ Department of Nephrology, University Hospital Germans Trias i Pujol, Badalona (Barcelona), Catalonià, Spain.
- ⁸ Department of Health Sciences, Renal Division, University of Milan, Italy
- ⁹ Nephrology Department, Hospital Curry Cabral | ULS São José, Rua da Beneficência nº8, 1050-099, Lisbon, Portugal and Nova Medical School, Lisbon, Portugal
- ¹⁰ Department of Nephrology, Copenhagen University Hospital-Herlev, Copenhagen, Denmark
- ¹¹ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- ¹² Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
- ¹³ Department of Endocrinology and Metabolism, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
- ¹⁴ Department of Translation and Precision Medicine, Sapienza University of Rome, Italy
- ¹⁵ Institute of Pharmaceutical Science, King's College London, London, UK and
Department of Evelina Pharmacy, Guys' & St Thomas' NHS Foundation Trust, London, UK
- ¹⁶ Renal Unit, UCL Great Ormond Street Hospital for Children; University College London, London, UK
- ¹⁷ Department of Microbiology, Immunology and Transplantation; Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium

Correspondence to:

Pieter Evenepoel;

E-mail: Pieter.Evenepoel@uzleuven.be

GRAPHICAL ABSTRACT



ABSTRACT

Vitamin D deficiency is common in patients with chronic kidney disease (CKD) and associates with poor outcomes. Current clinical practice guidelines recommend supplementation with nutritional vitamin D as for the general population. However, recent large-scale, clinical trials in the general population failed to demonstrate a benefit of vitamin D supplementation on skeletal or non-skeletal outcomes, fueling a debate on the rationale for screening for and correcting vitamin D deficiency, both in non-CKD and CKD populations. In a collaboration between the European Renal Osteodystrophy initiative of the European Renal Association (ERA) and the European Society for Paediatric Nephrology (ESPN), an expert panel performed an extensive literature review and formulated clinical practice points on vitamin D supplementation in children and adults with CKD and after kidney transplantation. These were reviewed by a Delphi panel of members from relevant working groups of the ERA and ESPN. Key clinical practice points include recommendations to monitor for, and correct, vitamin D deficiency in children and adults with CKD and after kidney transplantation, targeting 25-hydroxyvitamin D levels >75 nmol/L (>30 ng/mL). While vitamin D supplementation appears well-tolerated and safe, it is recommended to avoid mega-doses (≥ 100000 IU) and very high levels of 25 hydroxyvitamin D (>150–200 nmol/L, or 60–80 ng/mL) to reduce the risk of toxicity. Future clinical trials should investigate the benefit of vitamin D supplementation on patient-relevant outcomes in the setting of vitamin D deficiency across different stages of CKD.

Keywords: chronic kidney disease – mineral and bone disorder, kidney transplantation, parathyroid hormone, renal osteodystrophy, vitamin D

Introduction

Vitamin D deficiency is common in patients with chronic kidney disease (CKD) and associates with poor outcomes. Even so, the evaluation and management of vitamin D deficiency in patients with CKD remains controversial. Therapy with active vitamin D compounds in patients with CKD failed to improve outcomes and is known to confer risk of hypercalcaemia.¹⁻³ Current clinical practice guidelines state that it is reasonable to reserve the use of calcitriol and active vitamin D analogues for patients with advanced CKD and severe and progressive hyperparathyroidism.^{4,5} Nutritional vitamin D supplementation is recommended as for the general population.^{4,5}

Recently, large, randomised, controlled trials, such as the vitamin D and omega-3 Trial (VITAL), failed to show health benefits of nutritional vitamin D supplementation in the general population, even in individuals with low 25-hydroxy vitamin D (25(OH)D) levels at baseline.^{6,7} Following the publication of these trials, key opinion leaders suggested that health care providers should stop screening for vitamin D deficiency,⁸ and that people should stop taking vitamin D supplements.⁹ Others advocated for a more nuanced interpretation.¹⁰⁻¹² The results of these trials are diffusing into the nephrology community,¹³ raising the question of whether nutritional vitamin D supplementation should also be abandoned in patients with CKD.

Besides this ‘existential question’ on the need for screening for and correcting vitamin D deficiency, other questions related to the optimal monitoring¹⁴ (quantitative measures vs vitamin D metabolites ratios, total vs free 25(OH)D) and treatment strategy (target 25(OH)D level, combination therapy of nutritional vitamin D and active vitamin D compounds) in patients with CKD should be considered as well.¹⁵ This consensus statement addresses these questions and aims to provide guidance on how to monitor for and correct vitamin D deficiency using nutritional vitamin D supplements in children and adults with CKD, on dialysis, and after kidney transplantation, anno 2025.

Methods

Developing the PICO questions

We developed clinical questions to be addressed and framed them in a searchable format, with specification of the population (P) to whom the statements would be applicable; the intervention (I) considered; the comparator (C; which may be placebo, “no therapy” or alternative intervention); and the outcomes (O) of interest. Our PICO terms were as follows:

Population: All patients (children and adults) with CKD grades 2-5, on dialysis, and after kidney transplantation

Intervention: Nutritional vitamin D supplementation (cholecalciferol, ergocalciferol, calcifediol)

Comparator: Placebo or no supplementation, standard of care, active vitamin D compounds

Outcomes:

- Patient-level outcomes: All-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), falls in the elderly, fractures, growth in children.
- Bone imaging: Bone mineral density (BMD)
- Bone histology: Measures of bone turnover, mineralization, and volume
- Surrogate measures of cardiovascular disease: vascular stiffness, vascular calcification, endothelial dysfunction and blood pressure
- Biomarkers: Parathyroid hormone (PTH), serum calcium (for toxicity), fibroblast growth factor 23 (FGF23), total alkaline phosphatase and bone turnover markers (particularly non-renal excreted markers such as bone-specific alkaline phosphatase, BALP), 25(OH)D and its metabolites, vitamin D metabolic ratio(s)

Outcomes outside the scope of this review include the potential effects of vitamin D supplementation on progression of CKD and albuminuria, infection risk, malignancies, inflammation, autoimmune diseases and others.

Literature search

A comprehensive literature search was conducted with the aim of summarizing available evidence based on the following hierarchy of studies; systematic meta-analysis, trials with clinical outcomes, trials with intermediate outcomes, prospective cohort studies with clinical outcomes, and cross-sectional studies with intermediate outcomes when higher level of evidence was not available. Existing guidelines on recommended daily intake and target ranges of vitamin D for the general population were reviewed. In the absence of applicable studies, guidance is based on expert opinion.

Framing advice

Summary of the available evidence from the literature are presented as ‘Key evidence points’, while ‘Clinical practice points’ represent the resulting clinical practice recommendations. The final draft of the manuscript was sent to members of the CKD-mineral and bone disorder (CKD-MBD) working group of the European Renal Association and the CKD-MBD and Dialysis working groups of the European Society for Paediatric Nephrology (ESPN) with an e-questionnaire to provide a level of agreement on a 5-point scale (strongly disagree, disagree, neither agree nor disagree, agree, strongly agree) for the practice points. Participants were also given the opportunity of providing direct feedback, including suggestions for re-wording of the practice points. A priori, an agreement of >70% was required for each statement. If this condition was not fulfilled, the practice point would be discussed and adapted by the writing team.

Q1: What are the current recommendations for vitamin D supplementation in the general population?

1.1 Vitamin D metabolism in health

Key evidence points

- Dermal production upon ultraviolet-B light exposure is the most important source of vitamin D in humans as most foods have a low natural content of vitamin D.
- Liver 25-hydroxylase activity is metabolically controlled, rather than constitutively determined.
- Renal 1,25 dihydroxy vitamin D (1,25(OH)₂D) production and degradation is tightly controlled by the hormones that govern mineral metabolism (PTH, FGF23, vitamin D metabolites).
- Extrarenal 1,25(OH)₂D production is largely substrate-dependent and may assist in maintaining circulating 1,25(OH)₂D levels, at least in conditions of insufficient renal production.

Background and rationale

Vitamin D is not a single compound but refers to a group of over 50 metabolites. Cholecalciferol (vitamin D₃) and ergocalciferol (vitamin D₂) are the two parent forms of vitamin D. The dietary intake of vitamin D is limited, as most foods (apart from oily fish¹⁶) have a low natural content of vitamin D. In most countries, the average daily intake of vitamin D is <5 µg (1 µg = 40 IU), and even in countries where foods are enriched with vitamin D, the total vitamin D intake is often lower than 10 µg/d.¹⁷ Thus, humans are largely dependent on ultraviolet-B radiation induced cutaneous synthesis of vitamin D₃ (cholecalciferol).¹⁶ Vitamin D is inactive and requires several metabolic steps, first by hydroxylation in the liver (mostly, but not exclusively, by *CYP2R1*, 25-hydroxylase) into 25(OH)D, followed by a second hydroxylation by *CYP27B1* (1-α-hydroxylase) into 1,25(OH)₂D to become fully active (**Figure 1**).¹⁸ *CYP24A1* is the main enzyme responsible for the catabolism of all vitamin D metabolites. Through a multistep pathway, this catabolism results in a large number of mostly inactive metabolites with side chain modifications, ultimately ending with calcitric and calcioic acid. Recent findings indicate that *CYP2R1* expression is not constitutively determined, but under the control of metabolic signals induced by energy metabolism (fasting, diabetes) or exposure to high-dose glucocorticoids.^{19,20} In contrast to *CYP2R1*, *CYP27B1* and *CYP24A1* are widely expressed across different body tissues.²¹ Renal *CYP27B1* and *CYP24A1* expression levels are transcriptionally regulated, mainly by the hormones of mineral metabolism, PTH, FGF23²², and 1,25(OH)₂D. Reciprocal regulation of *CYP27B1* and *CYP24A1* in the kidney acts to raise or lower 1,25(OH)₂D to maintain physiologically appropriate levels of the hormone (**Figure 2**). In extra-renal tissues, hormonal regulation of *CYP27B1* is variable and likely tissue specific (**Figure 3**).²³⁻²⁶ *CYP24A1* regulation is limited to induction by 1,25(OH)₂D,²⁷ which, at least in osteoblasts, may be amplified by

PTH²⁸. Production of 1,25(OH)₂D in extra-renal tissues seems mainly driven by substrate availability²⁹ with activation/up-regulation by inflammatory mediators such as lipopolysaccharides and interferon-gamma³⁰.

Vitamin D metabolites in serum are bound with high affinity to the specific vitamin D binding protein (DBP), and to a lesser extent to albumin. DBP is highly polymorphic and circulates in high concentrations, so that the free concentrations of all vitamin D metabolites are low. For most tissues, only the unbound metabolites can cross the cell membrane through diffusion. In the kidneys, parathyroid glands and placenta, 25(OH)D and 1,25(OH)₂D bound to DBP may also enter cells by endocytosis via megalin/cubilin.³¹ Once internalized, 1,25(OH)₂D binds to the vitamin D receptor (VDR), present in most cells. Vitamin D regulates a large number of genes, mainly related to calcium and phosphate metabolism, but also others that are involved in iron metabolism, the immune and cardiovascular systems, and overall regulation of cell proliferation and differentiation.³²

A prevailing paradigm in vitamin D metabolism is that the kidney is the only relevant source of circulating 1,25(OH)₂D, while extrarenal *CYP27B1* activity serves only paracrine or autocrine functions.^{18,33} This paradigm is challenged by experimental data from a kidney-specific *CYP27B1* pseudo-null mouse model³⁴ and by clinical data in anephric patients^{29,35}, which indicate that extrarenal *CYP27B1* activity may contribute to maintaining circulating 1,25(OH)₂D levels, at least in conditions of defective renal *CYP27B1* activity (*Figure 3*).

1.2 Nutritional vitamin D targets and supplementation guidelines in the general population

Key evidence points

- Infants and small children should be supplemented with vitamin D (400-600 IU/d), at least during their first years of life.
- Adults, especially elderly and pregnant individuals, should have access to vitamin D supplementation, but recommended doses vary widely (from 200 IU to 2000 IU/d), in line with the uncertainty regarding the minimal desirable serum concentration of 25(OH)D.

Background and rationale

Several groups of people have a shortfall between their requirement for vitamin D and the combined cutaneous synthesis and food intake and may therefore need vitamin D supplementation.

Governments, scientific societies, and expert panels are regularly updating recommendations for the intake of vitamin D, especially for groups that should (infants) or prefer to (especially elderly individuals) avoid direct sunlight exposure. There is a fair consensus that all infants and small children should receive 400-600 IU daily at least during their first years of life and that pregnant women and elderly should have access to vitamin D supplementation.³⁶ The recommended doses for adults vary widely (from 200 IU to 2000 IU/d),¹⁶ in line with disagreement regarding the minimal desirable serum concentration of 25(OH)D (*Table 1*). All guidelines agree that 25(OH)D levels <30 nmol/L (<12

ng/mL) should be avoided and that levels >75 nmol/L (>30 ng/ml) are sufficient. Adequate vitamin D status by this definition is probably reached by less than 50% of the world population, at least in winter.³⁷ In 2019, NHANES reported a prevalence of vitamin D deficiency (<30 nmol/L or 12 ng/mL) of 5% in the United States, with no change in prevalence between 2003 and 2014.³⁸

Vitamin D deficiency has been defined in the context of skeletal mineralisation. Serum 25(OH)D level <30 nmol/l (<12 ng/mL) strongly increases the risk of rickets in children and osteomalacia in adults.^{39,40} This 25(OH)D level is also consistent with the threshold below which active intestinal calcium absorption decreases.⁴¹ Vitamin D adequacy is most often defined as the vitamin D level that minimizes circulating PTH levels. Observational studies are inconsistent regarding this threshold, but clinical trials demonstrate that vitamin D supplementation results in a decrease in PTH if the baseline 25(OH)D is <50 nmol/L (<20 ng/mL).^{42,43} Conversely, large-scale randomised, controlled trials and Mendelian randomisation studies failed to demonstrate a benefit of vitamin D supplementation for skeletal or extra-skeletal health in adults with 25(OH)D levels >50 nmol/L (>20 ng/mL).⁴⁴ Thus, in summary, the recommendations for the general population is to maintain serum 25(OH)D above 50-75 nmol/L, mainly to ensure skeletal health, as extra-skeletal benefits of vitamin D supplementation remains controversial.

1.3 Vitamin D metabolism in CKD

Key evidence points

- CKD is a state of dysregulated vitamin D metabolism and vitamin D hypo-responsiveness.
- CKD is likely a state of extrarenal CYP27B1 activation with extra-renal production of 1,25-dihydroxyvitamin D.

Background and rationale

Patients with CKD have a high prevalence of vitamin D deficiency.⁴⁵⁻⁴⁷ Several underlying mechanisms have been proposed, including: (1) reduced ingestion of foods high in vitamin D content, (2) reduced endogenous synthesis of vitamin D₃ in the skin due to reduced sunlight exposure or dermopathy, (3) increased FGF23-mediated vitamin D catabolism, and (4) increased losses, either through the kidneys (e.g. nephrotic syndrome^{48,49}) or the dialysate (peritoneal dialysis^{50,51}). It remains a matter of ongoing debate whether impaired liver 25-hydroxylase activity contributes to the low 25(OH)D levels in patients with CKD. Experimental kidney failure and hyperparathyroidism have been shown to decrease several *CYP450* isoforms involved in the 25-hydroxylation of vitamin D, but not *CYP2R1*.⁵² Endotoxaemia may be a common culprit of 25(OH)D deficiency in patients with CKD, diabetes, and non-alcoholic fatty liver disease.^{19,53,54} 25(OH)D levels in the general population show seasonal fluctuations, vary across ethnic groups and according to dietary habits⁵⁵, and are lower in obese individuals⁵⁶. There is no reason to assume that these sources of variability do not also apply in the setting of CKD. Studies comparing 25(OH)D levels in patients with CKD and otherwise healthy

individuals, matched for key variables such as age, body mass index, ethnicity, and season are scarce.^{57,58} As such, it is hard to estimate the direct impact of CKD on vitamin D deficiency. 1,25(OH)₂D levels decline as kidney failure progresses.⁵⁷ This decline seems mainly driven by the rising levels of FGF23, since FGF23-neutralizing antibodies have been shown to normalize serum 1,25-dihydroxyvitamin D levels in experimental models of CKD.^{59,60} Cohort studies also show decreasing levels of the catabolic product 24,25(OH)₂D paralleling kidney function decline,⁶¹ suggesting overall impaired *CYP24A1* activity, possibly as a consequence of reduced 1,25(OH)₂D levels.

The impact of CKD on extrarenal vitamin D metabolism is not well-defined, but it may be hypothesized that there is an increase in the extrarenal contribution to circulating levels of 1,25(OH)₂D as kidney function declines. CKD enhances both the expression and efficiency of *CYP27B1* in peripheral blood monocytes as compared to healthy volunteers.^{23,62} Microinflammation, a common finding in patients with CKD,⁵⁴ is a plausible driver of increased extrarenal *CYP27B1* activity.²³ Of interest, the extrarenal production of 1,25(OH)₂D seems to be highly substrate-driven, which may have implications for target levels of 25(OH)D in CKD.²⁹ The cellular uptake of 25(OH)D and its affinity for *CYP27B1*, conversely, are impaired in CKD, and may be partly restored by 1,25(OH)₂D supplementation.⁶² In addition to a decreased production of 1,25(OH)₂D, altered expression of the VDR or altered binding properties of the hormone receptor complex to DNA could also contribute to impaired 1,25(OH)₂D signalling in CKD.^{63,64} Thus, CKD qualifies as a state of overall stagnant vitamin D metabolism, where both production and degradation of 1,25(OH)₂D are suppressed.⁶¹ The clinical systemic implications of extra-renal production of 1,25(OH)₂D remains unclear.

1.4 Vitamin D metabolism in incident kidney transplant recipients

Key evidence points

- 25(OH)D levels show a transient decline early after kidney transplantation.
- Renal production of 1,25(OH)₂D recovers after kidney transplantation paralleling kidney graft function.

Background and rationale

Low levels of vitamin D are common after kidney transplantation,⁶⁵⁻⁶⁷ despite an increased focus on supplementation in recent years.⁶⁸ Longitudinal studies show a transient decline in 25(OH)D levels shortly after transplantation,^{69,70} which may be related to decreased vitamin D production in the skin (reduced sunshine exposure), impaired hepatic 25-hydroxylase activity (glucocorticosteroids²⁰) or increased degradation (mediated by FGF23). Parallel to the recovery of kidney function, and progressive decreases in PTH and FGF23, 1,25(OH)₂D levels rapidly increase from 3 months post-transplant onwards.²⁹ Of interest, patients who were able to maintain their 25(OH)D stores pre-transplant show a greater increase in 1,25(OH)₂D levels in the early post-transplant period.⁶⁹⁻⁷¹

Q2: What are the (pre)-analytical issues of vitamin D measurements and monitoring?

2.1 Analytical considerations

Key evidence points

- LC-MS/MS is the method of choice for measuring vitamin D metabolites, particularly in patients with CKD.
- The added value of the assessment of free vitamin D or metabolic ratios is uncertain.

Background and rationale

The most accurate approach to measure 25(OH)D in patients with advanced CKD is by liquid chromatography coupled with mass spectrometers in tandem (LC-MS/MS). This methodology brings an added advantage in its ability to quantify metabolites, e.g. the metabolite 24,25(OH)₂D which is produced by the enzyme *CYP24A1* and is the first step of the metabolization pathway of 25(OH)D. This metabolite is used to calculate the vitamin D metabolic ratio, which is further discussed below. Despite being the method of choice for quantifying 25(OH)D, LC-MS/MS is not widely implemented in clinical practice. Instead, many laboratories rely on commercially available immunoassays. Unfortunately, the vast majority of these immunoassays are inaccurate in the context of advanced CKD.^{72,73} A notable under-recovery, exceeding 20% of the metabolite, is observed, with no clear explanation beyond the alteration in the uremic matrix of these patients, which diverges from the matrix typically used for assay calibration, resulting in what is referred to as "matrix effects". As a consequence, the traditional cut-offs used to delineate vitamin D sufficiency and insufficiency should probably not be applied to these immunoassays, even if they adhere to full standardization according to the Vitamin D Standardization Program criteria and are impeccably traceable to reference methods. Additionally, immunoassays do not uniformly quantify vitamin D₂ metabolites (such as ergocalciferol), contributing to an elevated level of uncertainty in the reported values.

The ratio between the catabolic product 24,25(OH)₂D and 25(OH)D, termed the *vitamin D metabolic ratio*, has been proposed as a measure of vitamin D status, with the rationale that lower levels of the catabolic product would indicate functional vitamin D deficiency.^{74,75} As discussed in the previous section, vitamin D catabolism is certainly affected by CKD, with levels of 24,25(OH)₂D decreasing as kidney function declines.^{76,77} The 24,25(OH)₂D response to vitamin D supplementation is also less pronounced in patients with CKD compared to kidney-healthy populations.^{78,79} In keeping with this, the vitamin D metabolic ratio decreases more prominently than 25(OH)D levels as CKD progresses.⁸⁰ However, whether this decrease is due to functional vitamin D deficiency or rather *CYP24A1* dysfunction in CKD is not clear. Reduced 25(OH)D clearance has been demonstrated in patients with CKD,⁸¹ indicating the latter and making the interpretation of metabolic ratios in CKD difficult. In one of the few studies to investigate the potential clinical value of the vitamin D metabolic ratio in CKD, a

lower ratio was associated with cardiovascular events; however, the association disappeared after adjusting for kidney function.⁸²

The majority of vitamin D metabolites circulate bound to DBP and albumin (>99%) and, according to the free hormone hypothesis, may not be able to exert biological effects in most tissues. The utility of determining free vitamin D is a subject of ongoing debate.⁸³ The free fraction of vitamin D can be estimated mathematically through an equation that takes into account the levels of 25(OH)D, albumin, and DBP, along with affinity coefficients, akin to the approach published by Vermeulen *et al.* for free testosterone.⁸⁴ DBP should be measured using LC-MSMS or a method utilizing polyclonal antibodies to avoid under-recoveries linked to DBP polymorphism. An LC-MS/MS method for DBP quantitation has been published⁸⁵ and international standards are readily available. In addition to the analytical considerations, the calculations utilized are based on multiple assumptions and have not been validated in different disease conditions.⁸³ Another option for direct measurement of free vitamin D is through a commercially available two-step competitive ELISA assay.⁸⁶ In this approach, a monoclonal antibody against 25(OH)D is bound to a solid phase, which is supposed to selectively capture the free forms while excluding the bound ones. Subsequently, the quantification of this free form is achieved with a spectrophotometer. Alternatively, free vitamin D can be determined by an LC-MS/MS method, utilizing an equilibration dialysis step for sample preparation.⁸⁷ Of note, a recent comparison of both 'direct' methods revealed significant differences.⁸⁷ Measurement of free vitamin D is currently not recommended for the healthy background population,⁸ and with only a handful of studies investigating free vitamin D in CKD⁸⁸⁻⁹⁰, there is insufficient evidence to consider the clinical utility in this setting.

Measuring 1,25(OH)₂D is more complex than 25(OH)D as it circulates in the picomolar range, at concentrations approximately 1000 times lower than its precursor. Unlike the latter, there is currently no reference method available for 1,25(OH)₂D. Given the lack of clinical support for determining 1,25(OH)₂D in CKD, analytical challenges will not be further discussed.

In summary, 25(OH)D remains the preferred biomarker of vitamin D status. LC-MS/MS is the recommended method for determining vitamin D metabolites in CKD, particularly in later stages, but may not (yet) be widely available in clinical practice. Commercially available immunoassays should adhere to the current analytical standards and be traceable by the Vitamin D Standardization Program.

2.2 Monitoring strategy

Clinical practice points

- In patients with CKD G2-5D, we suggest measuring 25(OH)D concentrations at first presentation, with repeated analysis 3 months after any changes to vitamin D supplementation, and at least annually thereafter.

- Routine monitoring of 1,25(OH)₂D levels, free vitamin D levels, and ratios between vitamin D metabolites are not recommended.

Background and rationale

Given the high prevalence of vitamin D deficiency and secondary hyperparathyroidism, and the apparent substrate dependence of *CYP27B1* activity in CKD, monitoring of vitamin D status seems reasonable in these patients. A tailored approach might be preferred, but practical guidance from clinical trials is lacking. Pragmatically, we suggest to measure 25(OH)D in patients with CKD G2-5D at first presentation and annually thereafter. A repeated analysis 3 months following 25(OH)D targeting intervention (e.g. change of supplementation dose or interval) may be advised to assess treatment response, as both the supplement chosen (particularly with over the counter dietary supplements) and several patient-related factors (obesity, proteinuria, dialysis regime, baseline 25(OH)D level) can influence the response between dose given and increase in 25(OH)D levels. Potential benefits should be weighed against increased costs. These issues are further discussed in section 5. We do not recommend the monitoring of 1,25(OH)₂D, free vitamin D, or the ratio between 24,25(OH)₂D and 25(OH)D in daily clinical practice pending additional evidence clarifying their clinical value.

Q3: Is there evidence for benefit of vitamin D supplementation on bone and mineral metabolism in CKD?

3.1 Vitamin D supplementation and PTH control in CKD

Key evidence points

- Vitamin D supplementation improves control of secondary hyperparathyroidism in adults and children with CKD.

Clinical practice points

- We recommend supplementing vitamin D to >75 nmol/L (>30 ng/mL) in adults and children with CKD G2-5D to delay the onset, or improve the control, of secondary hyperparathyroidism, recognizing that the effect in CKD G5-5D is uncertain.
- We suggest replenishing vitamin D before using an active vitamin D compound in CKD G2-3 and before or concomitantly with an active vitamin D compound in CKD G4-5D.

Background and rationale

Vitamin D deficiency is a well-known cause of secondary hyperparathyroidism, and the inverse relationship between PTH and 25(OH)D levels is also apparent in CKD.^{91,92} A recent meta-analysis found a significant reduction in PTH by supplementation with vitamin D in CKD G3-4, but noted small study sizes and heterogeneity in the supplement chosen (cholecalciferol, ergocalciferol, or calcifediol), dosages used, and duration of the studies to be important limitations.⁹³ Not all studies

were placebo-controlled, and some included participants regardless of vitamin D status at baseline⁹⁴⁻⁹⁶. Considering placebo-controlled trials in more detail, PTH reduction seems evident when achieving a target 25(OH)D >75 nmol/L (>30 ng/mL), particularly when using cholecalciferol (**Table 2**).^{94,97-113} Ergocalciferol appears less efficient in achieving PTH reduction despite sufficient increases in 25(OH)D.^{95,114-117} In a head-to-head comparison, cholecalciferol resulted in greater increases in 25(OH)D levels in patients with CKD G3-5 compared to an equal dose of ergocalciferol, and only cholecalciferol resulted in PTH suppression.¹⁰³ Increased catabolism of vitamin D₃ metabolites induced by ergocalciferol has been proposed as the explanation for the difference in clinical efficacy between these two vitamin D compounds.¹¹⁷ In addition, three randomised, controlled trials demonstrated PTH reduction with extended release calcifediol compared to placebo in patients with CKD G2-4.¹¹⁸⁻¹²¹ Very high levels of 25(OH)D were achieved in these trials, with successive PTH reduction, leading the authors to argue that a higher 25(OH)D target may be appropriate in CKD. Most, but not all, studies specifically included patients with vitamin D insufficiency, typically defined as 25(OH)D <50-75 nmol/L (20-30 ng/mL), and some further specified that patients should have secondary hyperparathyroidism^{98,102}. One study reported no overall difference in PTH levels after cholecalciferol supplementation in CKD G2-3, except in the subgroup of patients with hyperparathyroidism at baseline.⁹⁴ This raises the question of whether vitamin D monitoring and supplementation should be reserved for patients with secondary hyperparathyroidism. However, in children with CKD, the time to manifest hyperparathyroidism could be delayed with vitamin D supplementation,¹²² and in adults, vitamin D supplementation was found to be equally effective to an active vitamin D compound in achieving PTH target levels in CKD G3-4,¹¹⁶ which provides arguments for a more pre-emptive approach.

The effect of vitamin D supplementation on PTH control in CKD G5-5D is less certain than in earlier stages, with discordant findings in available trials (**Table 3**). Changes in concomitant medical therapy for secondary hyperparathyroidism (active vitamin D compounds, calcimimetics) may, to some degree, obscure the effect of vitamin D supplementation on PTH. Indeed, some studies reported decreased use of active vitamin D compounds in the intervention arm^{105,107}; however, others reported no change in dose^{111,112,115}. One study demonstrated that 1,25(OH)₂D levels increased to a similar degree with cholecalciferol vs alfacalcidol¹⁰⁴, and another that PTH reduction was greater with the combination of paricalcitol and cholecalciferol, compared to the active vitamin D compound alone,¹⁰⁸ which argues for a role of ensuring vitamin D sufficiency even in kidney failure. PTH reduction was also reported with vitamin D supplementation in prospective studies that did not include a control group.¹²³⁻¹²⁵ Thus, the effect of vitamin D supplementation on PTH control is clearly less certain in CKD G5-5D than in earlier stages. Considering the substrate-dependence of CYP27B1 activity in CKD G5-5D^{29,126}, a higher 25(OH)D treatment target could be argued for; however, there is no solid evidence to support this. Given the tolerability of vitamin D supplementation and the potential benefit, it seems prudent to avoid vitamin D deficiency in CKD G5-5D.

The ESPN has published comprehensive clinical practice recommendations for both vitamin D supplementation and active vitamin D therapy in children with CKD.^{5,127} In children with CKD G2-4, ergocalciferol given to a target of 25(OH)D >75 nmol/L (>30 ng/mL) delayed the onset of secondary hyperparathyroidism.¹²² A second study, including children with CKD G2-4 also demonstrated PTH reduction with high-dose cholecalciferol with approximately half of the cohort achieving a 30% reduction in PTH levels.¹²⁸ Lastly, in the C3 trial^{114,115}, which included children with CKD G2-4, lower PTH levels were seen when achieving 25(OH)D >75 nmol/L (>30 ng/mL)¹²⁹, and there was an inverse relationship between the 25(OH)D increase and the PTH decrease¹³⁰.

In conclusion, for both children and adults with CKD, vitamin D supplementation to a 25(OH)D target >75 nmol/L delays the onset of, or improves the control of, secondary hyperparathyroidism. Although the effect is less certain in CKD G5-5D, there is currently insufficient evidence to suggest differential 25(OH)D targets in patients with kidney failure.

3.2 Vitamin D supplementation and bone outcomes in CKD

Key evidence points

- There is no evidence for a benefit of vitamin D supplementation alone on the risk of bone loss and fractures in adults or children with CKD, or for improved growth in children with CKD.

Background and rationale

Vitamin D supplementation may benefit skeletal health indirectly through improved intestinal calcium absorption and suppression of secondary hyperparathyroidism,¹³¹ or directly through effects on bone mineralisation.¹³² However, whether fracture risk is reduced by vitamin D supplementation at the population level remains controversial.⁴⁴ A recent meta-analysis attempted to pool fracture data from trials of vitamin D supplementation in CKD, but the low number of events in each trial renders these analyses inconclusive.¹³³ Of two studies identified investigating the effect of vitamin D supplementation on intermediate bone outcomes (bone imaging), one was a combined intervention with calcium and cholecalciferol given to frail, elderly women with CKD G1-3.¹³⁴ This study concluded that there was an overall positive treatment effect on distal radius BMD, which did not differ based on baseline kidney function.¹³⁴ A second study included patients with CKD G5D receiving haemodialysis and investigated an intervention of cholecalciferol 5000 IU/d versus no vitamin D supplement on top of cinacalcet and calcitriol, and reported a non-significant trend towards improved BMD at the femoral neck with cholecalciferol.¹⁰⁷

Vitamin D deficiency has been associated with bone mineralisation defects both in the general population¹³⁵ and in CKD¹³⁶, but to our knowledge, there are no trials that inform on the effects of vitamin D supplementation on bone histomorphometry in (contemporary) patients with CKD. Trials of active vitamin D compounds demonstrate improvements in bone histology both in early¹³⁷ and late¹³⁸ stages of CKD, but it is difficult to separate any independent and direct effects of vitamin D in bone

from those mediated by improved control of hyperparathyroidism.¹³⁷ To our knowledge, there are no trials to inform on the effect of vitamin D supplementation on bone outcomes, including growth, in children with CKD. Thus, although there is biological plausibility, there is insufficient evidence to support beneficial effects on skeletal health by vitamin D supplementation beyond what results from improved PTH control.

3.3 Vitamin D metabolism, PTH control and bone outcomes in kidney transplant recipients

Key evidence points

- Vitamin D supplementation improves the control of hyperparathyroidism after kidney transplantation.
- Vitamin D supplementation may reduce the risk of bone loss and fractures after kidney transplantation.

Clinical practice points

- We suggest supplementing vitamin D to >75 nmol/L (>30 ng/mL) in kidney transplant recipients to reduce the risk of bone loss and fractures.

Background and rationale

As in the general population, low levels of vitamin D associate with poor outcomes post-transplant⁶⁷ including osteoporosis¹³⁹ and disturbed bone turnover and mineralisation¹⁴⁰. Five trials investigated the effect of vitamin D supplementation on bone or related biochemical outcomes after kidney transplantation (**Table 4**),¹⁴¹⁻¹⁴⁵ two of which were randomised, controlled trials.^{142,146} Tsujita *et al.* randomised recipients of a living donor kidney transplantation from 1 month post-transplant to either cholecalciferol 4000 IU/d or placebo for 12 months.¹⁴² Baseline 25(OH)D was notably low, at 25 nmol/L (10 ng/mL). Supplementation resulted in a substantial increase in 25(OH)D levels (to 100 nmol/L or 40 ng/mL) and a greater decrease in PTH than in the placebo group. The treatment effect on PTH was more pronounced in patients with good kidney graft function and lower baseline levels of calcium or 25(OH)D. Lumbar spine BMD was better preserved with vitamin D supplementation, which could be partly explained by the lower PTH levels. In the VITALE study, prevalent kidney transplant recipients with stable kidney graft function and 25(OH)D levels <75 nmol/L (<30 ng/mL) were randomised to either high or low dose of cholecalciferol for 24 months.¹⁴¹ The primary outcome was a composite of diabetes mellitus, cardiovascular disease, cancer or death (discussed in the next section), and symptomatic fractures were included as a secondary outcome. Fracture incidence was significantly lower in the high-dose cholecalciferol group, although the number of events were small (3 vs 12 events). There was a marginal PTH lowering effect of high-dose cholecalciferol, but no effect on BMD in a subgroup of patients with available dual-energy x-ray absorptiometry-scans. Two additional studies investigating effects of calcium and vitamin D supplementation on BMD in the first post-transplant year reported diverging results.^{144,145}

In conclusion, although the evidence is sparse, two well-performed randomised, controlled trials indicate benefit of vitamin D supplementation on bone outcomes after kidney transplantation, likely mediated through improved control of hyperparathyroidism.

Q4: Is there evidence for benefit of vitamin D supplementation on cardiovascular outcomes and all-cause mortality in CKD?

4.1 Vitamin D supplementation and cardiovascular outcomes and mortality in CKD

Key evidence points

- There is no evidence for a benefit of vitamin D supplementation on cardiovascular outcomes or all-cause mortality in CKD.
- No studies revealed clinically relevant cardiovascular safety concerns of vitamin D supplementation.

Background and rationale

It has been hypothesized that vitamin D deficiency contributes to a range of illnesses, beyond and unrelated to its role in disturbed mineral homeostasis and bone disease. These pleiotropic effects are assumed to also involve the cardiovascular system. This hypothesis is based on the finding that the VDR is expressed on many cells, including in cardiovascular tissues,¹⁴⁷ and on observational data that demonstrate an inverse association between 25(OH)D levels and the incidence of cardiovascular events and mortality, both in the general population^{148,149} and in patients with CKD^{150,151}. However, systematic reviews and meta-analyses on the effects of vitamin D supplementation on these outcomes in CKD have provided contradictory results.^{133,152} Importantly, recent large-scale intervention studies in the general population essentially refute the causality of this association. The VITAL trial recruited over 25000 participants who were randomised to either 2000 IU cholecalciferol or placebo (and to omega 3 fatty acids or placebo in a 2x2 factorial design).¹⁵³ The study was negative on its primary (incident invasive cancer or MACE) and secondary endpoints, and there was no effect modifications of any subgroup on MACE. In addition, there was no signal of beneficial effect of vitamin D supplementation within the subgroup with baseline 25(OH)D levels <50 nmol/L (<20 ng/mL), although the number of events were too small to reliably show a difference between the study arms. The absence of effect on cardiovascular morbidity and mortality confirmed findings from previous large trials in the general population.^{154,155} Moreover, a subsequent study from Australia, the D-Health

Trial, of comparable size to VITAL, found no indication of any benefit of vitamin D supplements on mortality risk, including cardiovascular mortality in the older general population.¹⁵⁶ One conclusion from these studies may be that vitamin D deficiency has no causal role in these non-skeletal outcomes. However, a recent Mendelian randomisation study from the UK biobank provided some evidence to the contrary.¹⁵⁷ Studying the association between *predicted* levels of 25(OH)D, based on a wide range of genetic determinants, and all-cause and cause-specific mortality, a sharp increase in risk emerged with 25(OH)D levels <25 nmol/L (<10 ng/mL), i.e. severe vitamin D deficiency (**Figure 4**). This ‘inflection level’ corresponds to the level of 25(OH)D below which 1,25(OH)₂D production becomes substrate dependent.¹⁵⁸ Importantly, baseline 25(OH)D levels of patients enrolled in the VITAL study were well above the range where according to the UK biobank study, 25(OH)D levels really matter (**Figure 4**). Thus, the population included in the VITAL study may have been too vitamin D replete to benefit from the intervention.

Next, the question arises whether data obtained in the general population can be applied to the CKD setting. The VITAL investigators failed to demonstrate effect modification by estimated glomerular filtration rate (eGFR)¹⁵⁹, but the number of participants with an eGFR<60 was low, limiting statistical power. So far, only one prospective trial examined the potential benefits of vitamin D supplementation on cardiovascular outcomes in a CKD population. The VITALE study randomised 538 kidney transplantation recipients to low or high dose cholecalciferol for two years.¹⁴¹ There was no difference between groups in the time to occurrence of the composite endpoint of diabetes, cancer, MACE or death, nor between any of the individual components.¹⁴¹ This study also warrants cautious interpretation given the relatively small sample size and short follow-up time.

One may speculate that the abovementioned ‘inflection level’ is either non-existing or higher in the setting of CKD, acknowledging the marked impact of CKD on vitamin D metabolism with 1,25(OH)₂D becoming increasingly substrate dependent as kidney function declines. This reasoning fuels the hope that the currently recruiting Survival Improvement with Cholecalciferol in Patients on Dialysis (SIMPLIFIED) study will yield meaningful results. SIMPLIFIED is a prospective, randomised, open-label, multicentre trial of cholecalciferol versus standard care in patients receiving dialysis. Approximately 4200 subjects from 65 dialysis units in the United Kingdom will be included

in the trial, and the primary objective is to determine the effect of cholecalciferol 60000IU every two weeks on patient survival.¹⁶⁰

Besides the above-mentioned trials on patient-relevant endpoints, a range of studies assessed the effects of vitamin D supplements on surrogate markers of cardiovascular health in people with CKD (**Table 5**), including pulse wave velocity (PWV; reflecting arterial stiffness)^{97,112,161,162} progression of arterial calcification¹⁶³, flow-mediated vasodilation (reflecting endothelial function)¹⁰⁰, left ventricle mass index,¹⁶⁴ and blood pressure^{94,97,165,166}. Overall, these studies found no benefit of vitamin D supplementation, with just a few nuances. In the study by Levin *et al.* the group allocated to calcifediol had an improved PWV after 6 months as compared to placebo.¹⁶¹ However, there were substantial differences of PWV at baseline, and when results were adjusted for that, the benefit was lost. The other exception was the study by Kumar *et al.* studying the effects of high dose cholecalciferol (300000 IU administered twice) on flow-mediated vasodilation in patients with CKD.¹⁰⁰ This study found a 5.5% improved endothelial function as compared to placebo after 16 weeks.

Of note, none of these studies revealed any safety issues with vitamin D supplements in terms of incidences of hypercalcemia or hyperphosphatemia. A few studies reported on the effects of vitamin D supplements on FGF23 (Supplementary **Table S1**).^{94,98,100,104,106,118,119,129,130} Overall, no effect was seen on FGF23 levels, although one study reported a transient increase in FGF23 in CKD patients with baseline vitamin D sufficiency (25(OH)D levels ≥ 75 nmol/L) allocated to cholecalciferol.⁶⁹ A recent meta-analysis of randomised clinical trials did indicate an increase in FGF23 levels with vitamin D supplements in a wide range of study populations, most of them without CKD.¹⁶⁷ The effect was modest, with a weighted mean difference in FGF23 levels of +21 pg/ml; however, it was more pronounced in people with kidney or heart failure (+300 pg/ml). FGF23 has consistently been associated with dismal clinical outcomes, but it is still unclear if FGF23 should be a treatment target in CKD.

Q5: What is the approach to the management and prevention of vitamin D deficiency in patients with CKD?

5.1 Pharmaceutical considerations

Clinical practice points

- We suggest using oral cholecalciferol to increase and maintain serum 25(OH)D concentration in the target range. If cholecalciferol is unavailable, oral ergocalciferol may be used in an equivalent dose.
- Oral administration of cholecalciferol should be preferred, with intramuscular administration reserved for patients with gastrointestinal malabsorption disorders.
- Vitamin D compounds should be administered by mouth and not through feeding tubes.

Background and rationale

Clinical evidence shows that nutritional vitamin D compounds are effective at increasing serum 25(OH)D levels in patients with CKD. Cholecalciferol seems to be more efficient than ergocalciferol, both for increasing serum 25(OH)D¹⁶⁸ and reducing serum PTH levels¹⁰³ (*Table 6*). This is consistent with findings in the general population (Supplementary *Table S3*)¹⁶⁹⁻¹⁷¹, and likely due to increased catabolism of vitamin D₃ metabolites induced by ergocalciferol, as previously discussed.

Studies of nutritional vitamin D have largely focused on the oral route of administration with only one study in CKD providing comparative data for the intramuscular route (Supplementary *Table S3*).¹⁷²

The pharmacokinetic profiles of vitamin D differ substantively between oral and intramuscular routes with respect to the rate at which peak levels are attained and decline, and therefore differences in when 25(OH)D levels were measured can confound comparisons. Thus, such comparisons need to be interpreted cautiously.¹⁷²⁻¹⁷⁴ Despite this limitation, the data collectively show that both routes of administration lead to an increase in serum 25(OH)D levels.¹⁷²⁻¹⁷⁴ However, intramuscular injections are invasive, and may cause pain, swelling, bleeding, and bruising at the injection site, and should therefore be reserved for patients with gastrointestinal malabsorption disorders. Vitamin D compounds are lipophilic, hence must be given by mouth and not through feeding tubes as they may adhere to the plastic¹⁷⁵, resulting in a lower and variable dose ingested.

Oral nutritional vitamin D products are commercially available in both pharmaceutical-grade and dietary supplements sold as over-the-counter preparations.^{176,177} While pharmaceutical-grade vitamin D products are subject to the same rigorous regulatory manufacturing standards as other medicines, a

number of studies have reported substantial variation in the actual vitamin D content compared to the value declared on the label (ranging from <10 to >200%) for over the counter vitamin D dietary supplements (Supplementary *Table S4*).¹⁷⁶⁻¹⁸¹ Thus, monitoring the response on 25(OH)D levels within a reasonable time-frame (arbitrarily set at 3 months, see section 2.2) after initiation of therapy is advisable.

5.2 Recommended dosage regimens in CKD

Clinical practice points

- We suggest using oral cholecalciferol with once daily, weekly, fortnightly, or monthly dosing schedules, adjusting the dose for baseline 25(OH)D levels and body size.
- In adults with CKD G2-5D or after kidney transplantation with serum 25(OH)D concentration <75 nmol/L (<30 ng/mL), we suggest an equivalent daily dose of 5000 – 7000 IU/day of cholecalciferol for a duration of 12 weeks to achieve the optimal target range. To maintain serum 25(OH)D concentration in the target range, we suggest continuous dosing with an equivalent daily dose of 2000 IU/day.
- In children with CKD G2-5D or after kidney transplantation with serum 25(OH)D concentration <75 nmol/L (<30 ng/ml), we suggest an equivalent daily dose of 3000-7000 IU/day of cholecalciferol for a duration of 12 weeks to achieve the optimal target range. To maintain serum 25(OH)D concentration in the target range, we suggest continuous dosing with an equivalent daily dose of 1000-2000 IU/day, adjusting for body size.
- We suggest avoiding exceeding doses of 100000 IU given as a single dose.

Background and rationale

The dose of vitamin D is a key determinant of the rate at which serum 25(OH)D concentration increases, although wide variability is observed between dose given and 25(OH)D levels achieved in both patients with CKD¹²² and in the general population¹⁸². Due to the heterogeneity in dosing regimens across studies (dose, frequency of dosing, duration of therapy) and variable patient-related factors (body weight, obesity, proteinuria, baseline 25(OH)D levels) which could affect the dose-response relationship,^{56,129,170,183} determining the optimal dose is challenging.^{127,133} Certain patient groups such as those that are obese, have high-grade proteinuria, or receive peritoneal dialysis therapy may require higher doses of cholecalciferol to achieve target 25(OH)D levels. The association between obesity and lower vitamin D levels is well described for the background population^{56,184} and is also

apparent in CKD¹²³. Proposed mechanisms include effects of metabolic status on hydroxylation of vitamin D in the liver (discussed in section Q1) and sequestration of vitamin D metabolites by adipose tissue. For glomerular diseases^{129,185} and peritoneal dialysis therapy^{50,51,186}, increased loss of DBP (in urine or dialysate) is hypothesized to be the reason for lower 25(OH)D levels and need for higher supplement doses to reach treatment targets.

There is no clear consensus on optimal dosages of vitamin D supplementation for adults or children with CKD. A commonly employed strategy is to use higher dose for a variable duration of 4-12 weeks to increase serum total 25(OH)D concentration to the target range followed by a lower dose as maintenance therapy.^{127,187} The vitamin D doses used in randomised, controlled trials in adults with CKD with PTH outcomes are shown in **Table 2+3** and **Figure 5+6**. There is no rationale for rapid correction of 25(OH)D deficiency, and the use of mega-doses is not recommended (see below). There is significant variation in the doses used in trials (equivalent daily dose: ~700 to 8000 IU), but collectively, it seems reasonable to suggest an equivalent daily dose of 5000-7000 IU/day of cholecalciferol for 12 weeks to achieve 25(OH)D >75 nmol/l (>30 ng/ml). Of note, the average baseline 25(OH)D level in studies ranged from 33-68 nmol/l (13.2-27.2 ng/ml), and individuals with lower 25(OH)D may require longer duration and higher doses to achieve the same target range. Equally, variation in individual responses, as indicated by the large standard deviations, suggests that personalised dosing regimens may be needed. As discussed above, in patients with CKD, 25(OH)D *production* is not substrate dependent, and there is a non-linear correlation between the dose given and the 25(OH)D level achieved.¹²² To maintain serum 25(OH)D >75 nmol/l (>30 ng/ml), continuation with a lower dosing regimen is advocated. In the only study in adults with non-dialysis-dependent CKD that examined cessation of treatment, serum 25(OH)D levels declined substantially at 6 weeks following treatment cessation.¹⁰³ There are few studies examining the optimal dose needed to maintain serum 25(OH)D, but the available data suggest an equivalent daily dose of 2000 IU/day of cholecalciferol.^{94,105,111,112}

In a randomised placebo-controlled trial of nutritional vitamin D in children with CKD, a modified version of the K/DOQI dosage recommendations was used, adjusting for both baseline 25(OH)D concentrations and the child's age. A target 25(OH)D >75 nmol/L (>30 ng/ml) was achieved in 80%

of children after 3 months of high-dose treatment whereas only for 60% of children on 1000 IU/d of ergocalciferol.¹²² A study comparing a daily equivalent dose of 3000-3500 IU of cholecalciferol (given as daily, weekly, or monthly regimens) in a cohort of children with CKD G3-4 reported that 78% of children achieved 25(OH)D \geq 75 nmol/l ($>$ 30 ng/ml), and after switching to 1000 IU/d, 65% maintained the target after 3 months, 70% after 6 months and 82% after 9 months.¹²⁹ Further, there are two randomised dose-comparison studies (Supplementary **Table S5**).^{188,189} Nadeem et al. randomised a cohort of children with CKD G3-5 to 1000 or 4000 IU/d and concluded that 1000 IU/d cholecalciferol is unlikely to achieve or maintain serum 25(OH)D \geq 75 nmol/L ($>$ 30 ng/ml).¹⁸⁸ The second study found that doses \leq 2000 IU/day for 4 months in children with very low 25(OH)D levels (median 12.5 nmol/l, or 5 ng/ml) failed to achieve the target 25(OH)D range.¹⁸⁹ Noticeably, these studies showed wide variation in responses, and in the only population pharmacokinetic modelling study of cholecalciferol in children with CKD, it was suggested that optimal dosing should take into consideration body weight, baseline 25(OH)D concentration, and the presence of proteinuria.¹⁸³

The *dosing interval*, vary considerable between trials, ranging from a single dose, daily, twice weekly, thrice weekly, weekly, fortnightly, to every 3, 4, 8 and 12 weeks.¹³³ Two studies that directly compared different dosing intervals reported comparable increase in serum 25(OH)D (**Table 7**).^{129,190} Thus, similar dosages administered at different dosing intervals seem equally efficacious at increasing serum 25(OH)D levels.

Extending the dosing interval is often accompanied by using higher doses, sometimes described as *megadoses*, although there is currently no consensus on the definition. Randomised, controlled trials in community-dwelling adults, usually the elderly, have reported a higher risk of falls and fractures in those who received very high doses of oral cholecalciferol,^{191 192} although a dose-response effect is unclear (Supplementary **Table S6**). Similar findings have not been reported in adults with CKD,¹¹⁰ but very few trials in CKD have used such high doses, and CKD trials are generally of short duration.

5.3 Use of (extended release) calcifediol in CKD

Clinical practice points

- Calcifediol may be considered instead of cholecalciferol or ergocalciferol in patients with CKD and liver failure.

- Extended release calcifediol may be considered in adults with CKD G3-4 and secondary hyperparathyroidism.

Background and rationale

There are some recent data on the use of calcifediol in adult patients with CKD (**Table 8**).^{118,119,161,193} Calcifediol is more hydrophilic, has a shorter half-life, and does not require hepatic 25-hydroxylation for its activation. It also has a more linear and predictable dose–response relationship and increases serum 25(OH)D levels more rapidly^{194,195} than ergocalciferol or cholecalciferol. In a placebo-controlled randomised, controlled trial, each microgram of orally consumed calcifediol was about 5 times more effective in raising serum 25(OH)D in healthy older adults in winter than an equivalent amount of cholecalciferol.¹⁹⁶ An *extended-release* calcifediol product, approved by the US Food and Drug Administration and the European Medicines Agency, is available in some countries, where it is registered for the treatment of secondary hyperparathyroidism in adults with CKD G3-4 and serum total 25(OH)D <75 nmol/L (<30 ng/ml). In trials investigating the use of extended release calcifediol in patients with CKD, the dosages utilized (30-90 µg/d) resulted in very high 25(OH)D levels, with successive PTH reduction until 25(OH)D levels exceeded 125 nmol/L (50 ng/mL) without any apparent toxicity.^{118,119} A few real-world observational studies are also available, reporting effectiveness of calcifediol in increasing serum 25(OH)D and reducing PTH without notable impact on serum calcium and phosphate.^{197,198} In a study directly comparing extended-release calcifediol to high-dose cholecalciferol and active vitamin D with low-dose cholecalciferol, extended-release calcifediol resulted in markedly higher 25(OH)D levels, with the target 25(OH)D >75 nmol/L reached for 100% of patients treated with extended-release calcifediol, 44% treated with cholecalciferol, and 15% treated with paricalcitol and low-dose cholecalciferol.¹²⁰ Thus, extended-release calcifediol may be considered when treating vitamin D deficiency in CKD, although it should be noted that the cost of this formulation is currently considerably higher than for ergocalciferol or cholecalciferol.

5.4 Safety considerations

Key evidence points

- Hypercalcaemia is rarely seen with nutritional vitamin D supplements when 25(OH)D levels are below 250 nmol/L (<100 ng/ml).
- The upper safe limit of 25(OH)D and the safety of long-term use of nutritional vitamin D in patients with CKD are unknown.

Clinical practice points

- In adults and children with CKD or after kidney transplantation, we suggest withholding nutritional vitamin D supplements when serum 25(OH)D levels are above 150-200 nmol/L (60-80 ng/ml), in the absence of hypercalcaemia.
- In patients with CKD and hypercalcaemia, check for and manage other causes of high calcium including iatrogenic (the use of active vitamin D compounds, high dialysate calcium, oral calcium-containing medications), CKD-related (presence of tertiary hyperparathyroidism), and non-CKD related conditions (malignancy, haematological conditions, sarcoidosis, hypovitaminosis A, etc) before stopping vitamin D supplementation.

Background and rationale

In the general population, large epidemiological studies have suggested a reverse J-shaped association between 25(OH)D levels and increased all-cause and cardiovascular mortality, with an increased risk at 25(OH)D >120 nmol/l (>48 ng/ml).¹⁹⁹⁻²⁰¹ A similar safety signal has not been reported in studies in CKD; however, while these studies indicate a linear reduction in all-cause mortality with increasing levels of 25(OH)D, their analyses have not examined 25(OH)D levels above 100 nmol/l.^{123 202,124} Keeping in mind the substrate dependency of vitamin D metabolism in advanced CKD, observational data in children¹²² and adults²⁹ suggest that 25OHD >100 nmoL/L (>40 ng/ml) are needed to achieve near-normal 1,25(OH)₂D levels in CKD, which could translate to a higher safe upper limit of 25(OH)D. Concurrently, in a recent meta-analysis there was no increased risk of hypercalcemia or hyperphosphatemia in studies of nutritional vitamin D in patients with CKD.¹³³ Thus, vitamin D supplements are unlikely to cause hypercalcemia unless 25(OH)D levels are substantially elevated, or there is inappropriate extra-renal CYP27B1 activity with a high degree of substrate dependence. A particular situation arises in the post-transplant setting, where 10-20% of patients present with mild hypercalcemia, with little spontaneous remission over time.²⁰³ Unfortunately, trials of vitamin D supplementation post-transplant have so far excluded patients with hypercalcemia.^{141,142} In *primary* hyperparathyroidism, vitamin D supplementation given to patients with hypercalcemia has been shown to decrease PTH levels prior to a parathyroidectomy, and to alleviate bone loss both before and after surgery, without meaningful increases in serum or urinary calcium.²⁰⁴ Similar studies should be considered in the post-transplant setting. Currently, significant heterogeneity in investigator-defined

thresholds for these biochemical measures, analytical issues, and short-duration of trials, make it impossible to determine the upper-safety limit and the safety of long-term use of nutritional vitamin D in patients with CKD.

Results of the Delphi survey

The Delphi survey revealed an overall high level of agreement. All but three clinical practice points reached the pre-defined goal of agreement, defined as being rated ‘Strongly agree’ or ‘Agree’ by more than 70% of the panel. Agreement was generally in the range of 80-90%, and disagreement (‘Disagree’ or ‘Strongly disagree’) did not exceed 10% for any of the practice points. The three practice points that failed to reach a 70% agreement received high ratings for ‘Neutral’ (27-33%), which may reflect hesitancy due to lack of conclusive evidence. Following discussions of the results of the Delphi survey, one practice point was removed (4.1), one was expanded upon in the discussion (5.1), and the last was modified for clarity (5.3). The full list of scores from the survey is available as *Supplementary Table S7*. All comments given in the Delphi survey was likewise reviewed by the core writing team, with subsequent minor adjustments to the clinical practice points and discussion. Many responses reflected personal practice with notable variations between responders, further highlighting the need for an evidence-informed consensus.

Research recommendations

- Data comparing vitamin D status of patients with CKD to the general population should be sought, to define whether CKD *per se* is a risk factor of vitamin D insufficiency.
- Research is needed to evaluate whether profiling of vitamin D metabolites beyond 25(OH)D will improve risk stratification and provide therapeutic guidance
- The optimal frequency of 25(OH)D measurement should be investigated, taking into consideration different supplementation strategies (for example cholecalciferol vs extended release calcifediol and different dosing regimens)
- (Pragmatic) trials are needed to evaluate the effect of nutritional vitamin D supplementation on meaningful skeletal and non-skeletal (particularly cardiovascular) outcomes across different stages of CKD and after kidney transplantation.
- Future trials should primarily include participants with clinically apparent vitamin D deficiency.

Concluding remarks

Despite consistent associations between vitamin D deficiency and morbidity and mortality both in the general population and in patients with CKD, there is no conclusive evidence for a benefit of vitamin D supplementation on patient-relevant skeletal or non-skeletal outcomes. However, CKD is a setting of severely affected vitamin D metabolism, which contributes to the complex mineral metabolism

disturbances of CKD-MBD, and vitamin D supplementation has been shown to improve the control of secondary hyperparathyroidism. Therefore, based on available evidence, we recommend monitoring for, and treating, vitamin D deficiency in adults and children with CKD across stages of disease and after kidney transplantation. Vitamin D supplementation is well-tolerated without prominent safety signals in CKD, but based on concerns raised in the background population, we suggest avoiding mega-doses of vitamin D and very high serum levels of 25(OH)D. Future research should focus on (pragmatic) clinical trials investigating the benefit of vitamin D supplementation on patient-relevant outcomes in the setting of vitamin D deficiency, across the spectrum of CKD.

DATA AVAILABILITY STATEMENT

The data underlying this article are available in the article and in its online supplementary material.

ACKNOWLEDGEMENTS

This consensus work was supported by an unrestricted educational grant by Vifor CSL. CSL-Vifor had no role in the design of the study, data analysis, or data interpretation for this manuscript.

FUNDING

This consensus work was supported by an unrestricted educational grant by Vifor CSL. CSL-Vifor had no role in the design of the study, nor in data analysis and data interpretation.

AUTHORS' CONTRIBUTIONS

P. Evenepoel was responsible for the conception and design of this work. P. Evenepoel, J. Bacchetta and R. de Jongh. drafted section Q1, E. Cavalier, M. Herrmann and S. Mazzaferro drafted section Q2, H.S. Jørgensen, A.C. Ferreira and M. Cozzolino drafted section Q3, M. Vervloet, D. Hansen and M. de Borst drafted section Q4 and R. Shroff, M. Wan and J. Bover drafted section Q5. The core writing team, H.S. Jørgensen, E. Cavalier, M. Vervloet, R. Shroff and P. Evenepoel drafted the manuscript. All authors contributed to the analysis and interpretation of data and gave their input to and helped revise the manuscript. All authors approved the final manuscript and accept accountability for the accuracy and integrity of this work.

CONFLICT OF INTEREST STATEMENT

J. **Bacchetta** reports support from Viatrix/Mylan; J. **Bover** reports support from Abbvie, Amgen, Astra Zeneca, CSL Vifor, GSK, Rubió and Sanofi; M. de **Borst** reports support from Amgen, Astra Zeneca, Bayer, CSL Vifor, Kyowa Kiri Pharma, Pharmacosmos, and Sanofi Genzyme; E. **Cavalier** reports support from Fujirebio, IDS and Roche Diagnostics; M.

Cozzolino reports support from Amgen and Vifor CSL; A.C. **Ferreira** report support from Astra Zeneca, Bayer CSL and Vifor Pharma; D. **Hansen** reports support from Astra Zeneca, Gedeon Richter, GSK, UCB Nordic and VIFOR pharma; M. **Herrmann** reports support from Roche Diagnostics, Sanofi, Shimadzu and Sysmex; H.S. **Jørgensen** reports support from Abiogen Pharma; S. **Mazzaferro** reports support from Amgen; R. **Shroff** reports support from Amgen, Astra Zeneca, Fresenius Medical Care and Vitaflo; M. **Vervloet** reports support from Astra Zeneca, Boehringer Ingelheim, Fresenius Medical Care, Medice and Vifor Pharma; R. de **Jongh** and M. **Wan** have no disclosures.

REFERENCES

- 1 Investigators, J. D. *et al.* Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. *JAMA* **320**, 2325-2334, doi:10.1001/jama.2018.17749 (2018).
- 2 Thadhani, R. *et al.* Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. *JAMA* **307**, 674-684, doi:10.1001/jama.2012.120 (2012).
- 3 Wang, A. Y. *et al.* Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. *J Am Soc Nephrol* **25**, 175-186, doi:10.1681/ASN.2013010103 (2014).
- 4 Ketteler, M. *et al.* Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney Int* **92**, 26-36, doi:10.1016/j.kint.2017.04.006 (2017).
- 5 Shroff, R. *et al.* Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis. *Nephrol Dial Transplant* **32**, 1114-1127, doi:10.1093/ndt/gfx080 (2017).
- 6 LeBoff, M. S. *et al.* Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. *N Engl J Med* **387**, 299-309, doi:10.1056/NEJMoa2202106 (2022).
- 7 LeBoff, M. S. *et al.* Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and Omega-3 Trial (VITAL). *J Bone Miner Res* **35**, 883-893, doi:10.1002/jbmr.3958 (2020).
- 8 Giustina, A. *et al.* Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows. *Endocr Rev*, doi:10.1210/endrev/bnae009 (2024).
- 9 Cummings, S. R. & Rosen, C. VITAL Findings - A Decisive Verdict on Vitamin D Supplementation. *N Engl J Med* **387**, 368-370, doi:10.1056/NEJMe2205993 (2022).
- 10 Bouillon, R., LeBoff, M. S. & Neale, R. E. Health Effects of Vitamin D Supplementation: Lessons Learned From Randomized Controlled Trials and Mendelian Randomization Studies. *J Bone Miner Res*, doi:10.1002/jbmr.4888 (2023).
- 11 Bouillon, R. *et al.* The health effects of vitamin D supplementation: evidence from human studies. *Nat Rev Endocrinol* **18**, 96-110, doi:10.1038/s41574-021-00593-z (2022).
- 12 Charoenngam, N., Shirvani, A. & Holick, M. F. The ongoing D-lemma of vitamin D supplementation for nonskeletal health and bone health. *Curr Opin Endocrinol Diabetes Obes* **26**, 301-305, doi:10.1097/MED.0000000000000508 (2019).
- 13 Vervloet, M. G., Hsu, S. & de Boer, I. H. Vitamin D supplementation in people with chronic kidney disease. *Kidney Int*, doi:10.1016/j.kint.2023.07.010 (2023).
- 14 Cavalier, E., Makris, K., Heijboer, A. C., Herrmann, M. & Souberbielle, J. C. Vitamin D: Analytical Advances, Clinical Impact, and Ongoing Debates on Health Perspectives. *Clin Chem*, doi:10.1093/clinchem/hvae056 (2024).

- 15 Melamed, M. L. *et al.* The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *Am. J. Kidney Dis* **72**, 834-845, doi:S0272-6386(18)30839-4 [pii];10.1053/j.ajkd.2018.06.031 [doi] (2018).
- 16 Bouillon, R. Comparative analysis of nutritional guidelines for vitamin D. *Nat. Rev. Endocrinol* **13**, 466-479, doi:nrendo.2017.31 [pii];10.1038/nrendo.2017.31 [doi] (2017).
- 17 Freisling, H. *et al.* Region-specific nutrient intake patterns exhibit a geographical gradient within and between European countries. *J Nutr* **140**, 1280-1286, doi:10.3945/jn.110.121152 (2010).
- 18 Bouillon, R. & Bikle, D. Vitamin D Metabolism Revised: Fall of Dogmas. *J. Bone Miner. Res* **34**, 1985-1992, doi:10.1002/jbmr.3884 [doi] (2019).
- 19 Roizen, J. D. *et al.* Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. *J. Bone Miner. Res* **34**, 1068-1073, doi:10.1002/jbmr.3686 [doi] (2019).
- 20 Aatsinki, S. M. *et al.* Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes. *Diabetes* **68**, 918-931, doi:10.2337/db18-1050 (2019).
- 21 Bikle, D. D., Patzek, S. & Wang, Y. Physiologic and pathophysiologic roles of extra renal CYP27b1: Case report and review. *Bone Rep* **8**, 255-267, doi:10.1016/j.bonr.2018.02.004 (2018).
- 22 Shimada, T. *et al.* FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *Bone Miner Res* **19**, 429-435 (2004).
- 23 Viaene, L. *et al.* Uremia Suppresses Immune Signal-Induced CYP27B1 Expression in Human Monocytes. *Am. J. Nephrol* **36**, 497-508, doi:000345146 [pii];10.1159/000345146 [doi] (2012).
- 24 Bacchetta, J. *et al.* Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. *J. Bone Miner. Res* **28**, 46-55, doi:10.1002/jbmr.1740 [doi] (2013).
- 25 Somjen, D. *et al.* 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. *Circulation* **111**, 1666-1671, doi:01.CIR.0000160353.27927.70 [pii];10.1161/01.CIR.0000160353.27927.70 [doi] (2005).
- 26 Kanemoto, Y. *et al.* Transcriptional Regulation of 25-Hydroxyvitamin D-24-Hydroxylase (CYP24A1) by Calcemic Factors in Keratinocytes. *J Nutr Sci Vitaminol (Tokyo)* **67**, 424-428, doi:10.3177/jnsv.67.424 (2021).
- 27 Meyer, M. B. *et al.* A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues. *The Journal of biological chemistry* **294**, 14467-14481, doi:10.1074/jbc.RA119.010173 (2019).
- 28 Armbrrecht, H. J. *et al.* Induction of the vitamin D 24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. *Endocrinology* **139**, 3375-3381, doi:10.1210/endo.139.8.6134 (1998).
- 29 Jørgensen, H. S. *et al.* Vitamin D Metabolites Before and After Kidney Transplantation in Patients Who Are Anephric. *Am J Kidney Dis* **Accepted for publication** (2024).
- 30 Stoffels, K. *et al.* Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. *J Bone Miner Res* **21**, 37-47, doi:10.1359/JBMR.050908 (2006).
- 31 Bikle, D. D. The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. *JBMR Plus* **5**, e10418, doi:10.1002/jbmr.10418 (2021).
- 32 Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L. & Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol Rev* **96**, 365-408, doi:10.1152/physrev.00014.2015 (2016).
- 33 Pike, J. W. & Meyer, M. B. The unsettled science of nonrenal calcitriol production and its clinical relevance. *J Clin Invest* **130**, 4519-4521, doi:10.1172/JCI141334 (2020).

- 34 Meyer, M. B. *et al.* Targeted genomic deletions identify diverse enhancer functions and generate a kidney-specific, endocrine-deficient Cyp27b1 pseudo-null mouse. *J. Biol. Chem* **294**, 9518-9535, doi:RA119.008760 [pii];10.1074/jbc.RA119.008760 [doi] (2019).
- 35 Dusso, A., Brown, A. & Slatopolsky, E. Extrarenal production of calcitriol. *Semin Nephrol* **14**, 144-155 (1994).
- 36 Braegger, C. *et al.* Vitamin D in the healthy European paediatric population. *J Pediatr Gastroenterol Nutr* **56**, 692-701, doi:10.1097/MPG.0b013e31828f3c05 (2013).
- 37 Feldman, D. & Pike, J. W. *Feldman and Pike's Vitamin D*. 5th edition edn, (Elsevier, 2023).
- 38 Herrick, K. A. *et al.* Vitamin D status in the United States, 2011-2014. *Am J Clin Nutr* **110**, 150-157, doi:10.1093/ajcn/nqz037 (2019).
- 39 Bouillon, R. & Carmeliet, G. Vitamin D insufficiency: Definition, diagnosis and management. *Best Pract Res Clin Endocrinol Metab* **32**, 669-684, doi:10.1016/j.beem.2018.09.014 (2018).
- 40 Munns, C. F. *et al.* Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. *J Clin Endocrinol Metab* **101**, 394-415, doi:10.1210/jc.2015-2175 (2016).
- 41 Need, A. G. *et al.* Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. *J Bone Miner Res* **23**, 1859-1863, doi:10.1359/jbmr.080607 (2008).
- 42 Lips, P. *et al.* A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. *J Clin Endocrinol Metab* **86**, 1212-1221, doi:10.1210/jcem.86.3.7327 (2001).
- 43 Malabanan, A., Veronikis, I. E. & Holick, M. F. Redefining vitamin D insufficiency. *Lancet* **351**, 805-806, doi:10.1016/s0140-6736(05)78933-9 (1998).
- 44 Bouillon, R., LeBoff, M. S. & Neale, R. E. Health Effects of Vitamin D Supplementation: Lessons Learned From Randomized Controlled Trials and Mendelian Randomization Studies. *J Bone Miner Res* **38**, 1391-1403, doi:10.1002/jbmr.4888 (2023).
- 45 Levin, A. *et al.* Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *kidney int* **71**, 31-38 (2007).
- 46 Wolf, M. *et al.* Vitamin D levels and early mortality among incident hemodialysis patients. *kidney int* **72**, 1004-1013 (2007).
- 47 Urena-Torres, P. *et al.* Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. *Am. J. Kidney Dis* **58**, 544-553, doi:S0272-6386(11)01018-3 [pii];10.1053/j.ajkd.2011.04.029 [doi] (2011).
- 48 Barragry, J. M. *et al.* Vitamin-D metabolism in nephrotic syndrome. *Lancet* **2**, 629-632, doi:10.1016/s0140-6736(77)92498-9 (1977).
- 49 Grymonprez, A. *et al.* Vitamin D metabolites in childhood nephrotic syndrome. *Pediatr Nephrol* **9**, 278-281, doi:10.1007/BF02254183 (1995).
- 50 Joffe, P. & Heaf, J. G. Vitamin D and vitamin-D-binding protein kinetics in patients treated with continuous ambulatory peritoneal dialysis (CAPD). *Perit Dial Int* **9**, 281-284 (1989).
- 51 Prytula, A. *et al.* Urinary and dialysate losses of vitamin D-binding protein in children on chronic peritoneal dialysis. *Pediatr Nephrol* **27**, 643-649, doi:10.1007/s00467-011-2045-0 (2012).
- 52 Michaud, J. *et al.* Reduced hepatic synthesis of calcidiol in uremia. *J. Am. Soc. Nephrol* **21**, 1488-1497, doi:ASN.2009080815 [pii];10.1681/ASN.2009080815 [doi] (2010).
- 53 Cani, P. D. *et al.* Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* **56**, 1761-1772, doi:db06-1491 [pii];10.2337/db06-1491 [doi] (2007).
- 54 Evenepoel, P., Stenvinkel, P., Shanahan, C. & Pacifici, R. Inflammation and gut dysbiosis as drivers of CKD-MBD. *Nat Rev Nephrol* **19**, 646-657, doi:10.1038/s41581-023-00736-7 (2023).
- 55 Mithal, A. *et al.* Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int* **20**, 1807-1820, doi:10.1007/s00198-009-0954-6 (2009).
- 56 Tobias, D. K. *et al.* Association of Body Weight With Response to Vitamin D Supplementation and Metabolism. *JAMA Netw Open* **6**, e2250681, doi:10.1001/jamanetworkopen.2022.50681 (2023).

- 57 Levin, A. *et al.* Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. *Kidney International* **71**, 31-38, doi:10.1038/sj.ki.5002009 (2007).
- 58 Kim, S. M. *et al.* Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. *J Ren Nutr* **24**, 20-25, doi:10.1053/j.jrn.2013.07.003 (2014).
- 59 Hasegawa, H. *et al.* Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. *kidney int* (2010).
- 60 Shalhoub, V. *et al.* FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. *J. Clin. Invest* **122**, 2543-2553, doi:10.1172/JCI61405 [pii];10.1172/JCI61405 [doi] (2012).
- 61 Bosworth, C. & de Boer, I. H. Impaired vitamin D metabolism in CKD. *Semin. Nephrol* **33**, 158-168, doi:S0270-9295(12)00278-1 [pii];10.1016/j.semnephrol.2012.12.016 [doi] (2013).
- 62 Gallieni, M. *et al.* Kinetics of monocytic 1 alpha-hydroxylase in renal failure. *AJP - Renal Physiology* **268**, F746-F753 (1995).
- 63 Glorieux, G. & Vanholder, R. Blunted response to vitamin D in uremia. *Kidney Int Suppl* **78**, S182-185, doi:10.1046/j.1523-1755.2001.59780182.x (2001).
- 64 Sawaya, B. P. *et al.* Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. *J. Am. Soc. Nephrol* **8**, 271-278 (1997).
- 65 Perrin, P. *et al.* Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* **13**, 2653-2663, doi:10.1111/ajt.12425 (2013).
- 66 Torres, A. *et al.* Mineral metabolism disorders, vertebral fractures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study). *Nefrologia* **36**, 255-267, doi:10.1016/j.nefro.2016.03.004 (2016).
- 67 Yin, S. *et al.* Prevalence of vitamin D deficiency and impact on clinical outcomes after kidney transplantation: a systematic review and meta-analysis. *Nutrition Reviews* **80**, 950-961, doi:10.1093/nutrit/nuab058 (2022).
- 68 Perrin, P. *et al.* Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation. *Transplantation* **101**, 1897-1905, doi:10.1097/TP.0000000000001449 (2017).
- 69 Evenepoel, P., Naesens, M., Claes, K., Kuypers, D. & Vanrenterghem, Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. *American Journal of Transplantation* **7**, 1193-1200 (2007).
- 70 Evenepoel, P. *et al.* Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. *CJASN* **3**, 1829-1836 (2008).
- 71 Wolf, M. *et al.* A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. *Transplantation* **100**, 184-193, doi:10.1097/TP.0000000000000823 [doi] (2016).
- 72 Cavalier, E. *et al.* Analytical and clinical evaluation of the new Fujirebio Lumipulse(R)G non-competitive assay for 25(OH)-vitamin D and three immunoassays for 25(OH)D in healthy subjects, osteoporotic patients, third trimester pregnant women, healthy African subjects, hemodialyzed and intensive care patients. *Clin Chem Lab Med* **54**, 1347-1355, doi:10.1515/cclm-2015-0923 (2016).
- 73 Depreter, B., Heijboer, A. C. & Langlois, M. R. Accuracy of three automated 25-hydroxyvitamin D assays in hemodialysis patients. *Clin Chim Acta* **415**, 255-260, doi:10.1016/j.cca.2012.10.056 (2013).
- 74 Hsu, S. *et al.* Validation of the 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) ratio as a biomarker of 25-hydroxyvitamin D(3) clearance. *J Steroid Biochem Mol Biol* **217**, 106047, doi:10.1016/j.jsbmb.2021.106047 (2022).

- 75 Ginsberg, C. *et al.* The Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration. *Clin Chem* **67**, 385-393, doi:10.1093/clinchem/hvaa238 (2021).
- 76 de Boer, I. H. *et al.* Estimated GFR and Circulating 24,25-Dihydroxyvitamin D3 Concentration: A Participant-Level Analysis of 5 Cohort Studies and Clinical Trials. *American Journal of Kidney Diseases* **64**, 187-197, doi:10.1053/j.ajkd.2014.02.015 (2014).
- 77 Bosworth, C. R. *et al.* The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. *Kidney International* **82**, 693-700, doi:10.1038/ki.2012.193 (2012).
- 78 Graeff-Armas, L. A., Kaufmann, M., Lyden, E. & Jones, G. Serum 24,25-dihydroxyvitamin D(3) response to native vitamin D(2) and D(3) Supplementation in patients with chronic kidney disease on hemodialysis. *Clin Nutr* **37**, 1041-1045, doi:10.1016/j.clnu.2017.04.020 (2018).
- 79 Stubbs, J. R., Zhang, S., Friedman, P. A. & Nolin, T. D. Decreased Conversion of 25-hydroxyvitamin D 3 to 24,25-dihydroxyvitamin D 3 Following Cholecalciferol Therapy in Patients with CKD. *Clinical Journal of the American Society of Nephrology* **9**, 1965-1973, doi:10.2215/CJN.03130314 (2014).
- 80 Lee, S. *et al.* 24,25-Dihydroxy Vitamin D and Vitamin D Metabolite Ratio as Biomarkers of Vitamin D in Chronic Kidney Disease. *Nutrients* **15**, doi:10.3390/nu15030578 (2023).
- 81 Hsu, S. *et al.* Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. *J Am Soc Nephrol* **32**, 188-198, doi:10.1681/ASN.2020050625 (2021).
- 82 Hsu, S. *et al.* Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study. *J Am Heart Assoc* **12**, e028561, doi:10.1161/JAHA.122.028561 (2023).
- 83 Bikle, D. D. & Schwartz, J. Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions. *Front Endocrinol (Lausanne)* **10**, 317, doi:10.3389/fendo.2019.00317 (2019).
- 84 Vermeulen, A., Verdonck, L. & Kaufman, J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* **84**, 3666-3672, doi:10.1210/jcem.84.10.6079 (1999).
- 85 Henderson, C. M. *et al.* Measurement by a Novel LC-MS/MS Methodology Reveals Similar Serum Concentrations of Vitamin D-Binding Protein in Blacks and Whites. *Clin Chem* **62**, 179-187, doi:10.1373/clinchem.2015.244541 (2016).
- 86 Heureux, N., Lindhout, E. & Swinkels, L. A Direct Assay for Measuring Free 25-Hydroxyvitamin D. *J AOAC Int* **100**, 1318-1322, doi:10.5740/jaoacint.17-0084 (2017).
- 87 Ishimine, N. *et al.* Development of free 25-hydroxyvitamin D3 assay method using liquid chromatography-tandem mass spectrometry. *Biosci Rep* **42**, doi:10.1042/BSR20221326 (2022).
- 88 van Hoof, H. J. *et al.* Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. *Eur J Endocrinol* **144**, 391-396, doi:10.1530/eje.0.1440391 (2001).
- 89 Chen, X. *et al.* Free 25-Vitamin D Is Correlated with Cardiovascular Events in Prevalent Hemodialysis Patients but Not with Markers of Renal Mineral Bone Disease. *Kidney Blood Press Res* **44**, 344-353, doi:10.1159/000499878 (2019).
- 90 Zeng, S. *et al.* Free vitamin D is independently associated with systolic blood pressure in diabetic patients with impaired kidney function. *Clin Nephrol* **97**, 63-69, doi:10.5414/CN110549 (2022).
- 91 Ennis, J. L., Worcester, E. M., Coe, F. L. & Sprague, S. M. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. *Journal of Nephrology* **29**, 63-70, doi:10.1007/s40620-015-0186-0 (2016).
- 92 Dhillon-Jhattu, S. *et al.* Vitamin D and Parathyroid Hormone Levels in CKD. *Am J Kidney Dis* **81**, 122-124, doi:10.1053/j.ajkd.2022.06.006 (2023).
- 93 Christodoulou, M., Aspray, T. J. & Schoenmakers, I. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating

- the Response to Supplementation and an Overview of Guidelines. *Calcif Tissue Int* **109**, 157-178, doi:10.1007/s00223-021-00844-1 (2021).
- 94 Alvarez, J. A. *et al.* High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr* **96**, 672-679, doi:10.3945/ajcn.112.040642 (2012).
- 95 Gravesen, E., Hofman-Bang, J., Lewin, E. & Olgaard, K. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5. *Scand J Clin Lab Invest* **73**, 107-116, doi:10.3109/00365513.2012.744464 (2013).
- 96 Petchey, W. G. *et al.* Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: a randomized controlled trial. *Nephrology (Carlton)* **18**, 26-35, doi:10.1111/j.1440-1797.2012.01662.x (2013).
- 97 Marckmann, P. *et al.* Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. *Nephrol Dial Transplant* **27**, 3523-3531, doi:10.1093/ndt/gfs138 (2012).
- 98 Westerberg, P. A. *et al.* High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study. *Nephrol Dial Transplant* **33**, 466-471, doi:10.1093/ndt/gfx059 (2018).
- 99 Yadav, A. K. *et al.* The Effect of Vitamin D Supplementation on Bone Metabolic Markers in Chronic Kidney Disease. *J Bone Miner Res* **33**, 404-409, doi:10.1002/jbmr.3314 (2018).
- 100 Kumar, V. *et al.* A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD. *J Am Soc Nephrol* **28**, 3100-3108, doi:10.1681/ASN.2017010003 (2017).
- 101 Dogan, E., Erkok, R., Sayarlioglu, H., Soyoral, Y. & Dulger, H. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. *Ren Fail* **30**, 407-410, doi:10.1080/08860220801964210 (2008).
- 102 Chandra, P. *et al.* Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. *Endocr Pract* **14**, 10-17, doi:10.4158/EP.14.1.10 (2008).
- 103 Wetmore, J. B., Kimber, C., Mahnken, J. D. & Stubbs, J. R. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. *Br J Nutr* **116**, 2074-2081, doi:10.1017/S000711451600427X (2016).
- 104 Matuszkiewicz-Rowinska, J. *et al.* Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group Study. *Front Med (Lausanne)* **8**, 781191, doi:10.3389/fmed.2021.781191 (2021).
- 105 Brimble, K. S. *et al.* Impact of Bioelectrical Impedance-Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. *Am J Kidney Dis* **79**, 820-831, doi:10.1053/j.ajkd.2021.08.022 (2022).
- 106 Alshahawey, M., El Borolossy, R., El Wakeel, L., Elsaid, T. & Sabri, N. A. The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study. *Nutr Metab Cardiovasc Dis* **31**, 626-633, doi:10.1016/j.numecd.2020.09.014 (2021).
- 107 Zheng, C. M. *et al.* Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. *Nutrients* **10**, doi:10.3390/nu10020196 (2018).
- 108 Zheng, J. Q. *et al.* Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. *Nutrients* **8**, doi:10.3390/nu8110708 (2016).
- 109 Wang, Y. *et al.* Efficacy of High-Dose Supplementation With Oral Vitamin D3 on Depressive Symptoms in Dialysis Patients With Vitamin D3 Insufficiency: A Prospective, Randomized, Double-Blind Study. *J Clin Psychopharmacol* **36**, 229-235, doi:10.1097/JCP.000000000000486 (2016).

- 110 Massart, A. *et al.* Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. *Am J Kidney Dis* **64**, 696-705, doi:10.1053/j.ajkd.2014.04.020 (2014).
- 111 Li, L. *et al.* Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. *PLoS One* **9**, e109998, doi:10.1371/journal.pone.0109998 (2014).
- 112 Hewitt, N. A., O'Connor, A. A., O'Shaughnessy, D. V. & Elder, G. J. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. *Clin J Am Soc Nephrol* **8**, 1143-1149, doi:10.2215/CJN.02840312 (2013).
- 113 Delanaye, P. *et al.* Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. *Nephrol Dial Transplant* **28**, 1779-1786, doi:10.1093/ndt/gft001 (2013).
- 114 Dreyer, G. *et al.* Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin d deficiency: an exploratory, double blind, randomised controlled trial. *PLoS One* **9**, e99461, doi:10.1371/journal.pone.0099461 (2014).
- 115 Bhan, I. *et al.* Nutritional vitamin D supplementation in dialysis: a randomized trial. *Clin J Am Soc Nephrol* **10**, 611-619, doi:10.2215/CJN.06910714 (2015).
- 116 Zhang, D., Li, H., Yin, D., Wang, L. & Ma, Y. Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial. *Eur J Pharmacol* **789**, 127-133, doi:10.1016/j.ejphar.2016.07.019 (2016).
- 117 Batacchi, Z. *et al.* Effects of Vitamin D(2) Supplementation on Vitamin D(3) Metabolism in Health and CKD. *Clin J Am Soc Nephrol* **12**, 1498-1506, doi:10.2215/CJN.00530117 (2017).
- 118 Sprague, S. M. *et al.* Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. *American Journal of Nephrology* **44**, 316-325, doi:10.1159/000450766 (2016).
- 119 Sprague, S. M. *et al.* Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. *Am J Nephrol* **40**, 535-545, doi:10.1159/000369939 (2014).
- 120 Strugnelli, S. A., Csomor, P., Ashfaq, A. & Bishop, C. W. Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease. *Kidney Dis (Basel)* **9**, 206-217, doi:10.1159/000529523 (2023).
- 121 Strugnelli, S. A., Sprague, S. M., Ashfaq, A., Petkovich, M. & Bishop, C. W. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. *American Journal of Nephrology* **49**, 284-293, doi:10.1159/000499187 (2019).
- 122 Shroff, R. *et al.* Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. *Clin J Am Soc Nephrol* **7**, 216-223, doi:10.2215/CJN.04760511 (2012).
- 123 Jean, G., Souberbielle, J. C. & Chazot, C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. *Nephrol Dial Transplant* **24**, 3799-3805, doi:10.1093/ndt/gfp370 (2009).
- 124 Jean, G. *et al.* Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. *Nephrol Dial Transplant* **23**, 3670-3676, doi:10.1093/ndt/gfn339 (2008).
- 125 Matias, P. J. *et al.* Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. *Clin J Am Soc Nephrol* **5**, 905-911, doi:10.2215/CJN.06510909 (2010).
- 126 Huish, S. A. *et al.* Low serum 1,25(OH)2D3 in end-stage renal disease: is reduced 1 α -hydroxylase the only problem? *Endocr Connect* **10**, 1291-1298, doi:10.1530/EC-21-0372 (2021).
- 127 Shroff, R. *et al.* Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. *Nephrol Dial Transplant* **32**, 1098-1113, doi:10.1093/ndt/gfx065 (2017).

- 128 Hari, P. *et al.* Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. *Pediatr Nephrol* **25**, 2483-2488, doi:10.1007/s00467-010-1639-2 (2010).
- 129 Iyengar, A. *et al.* Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial. *Nephrol Dial Transplant* **37**, 326-334, doi:10.1093/ndt/gfaa369 (2022).
- 130 Kamath, N. *et al.* Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease. *Pediatr Nephrol* **38**, 1907-1913, doi:10.1007/s00467-022-05790-0 (2023).
- 131 DeLuca, H. F. Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr* **80**, 1689S-1696S, doi:10.1093/ajcn/80.6.1689S (2004).
- 132 Bhan, A., Qiu, S. & Rao, S. D. Bone histomorphometry in the evaluation of osteomalacia. *Bone Reports* **8**, 125-134, doi:10.1016/j.bonr.2018.03.005 (2018).
- 133 Yeung, W. G. *et al.* Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. *Am J Kidney Dis* **82**, 543-558, doi:10.1053/j.ajkd.2023.04.003 (2023).
- 134 Bosworth, C. *et al.* The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. *Clin Nephrol* **77**, 358-365, doi:10.5414/cn107180 (2012).
- 135 Priemel, M. *et al.* Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* **25**, 305-312, doi:10.1359/jbmr.090728 (2010).
- 136 Coen, G. *et al.* 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. *Kidney Int* **68**, 1840-1848, doi:10.1111/j.1523-1755.2005.00603.x (2005).
- 137 Hamdy, N. A. *et al.* Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. *BMJ* **310**, 358-363, doi:10.1136/bmj.310.6976.358 (1995).
- 138 Cannella, G. *et al.* Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. *Kidney Int* **46**, 1124-1132, doi:10.1038/ki.1994.375 (1994).
- 139 Heaf, J., Tvedegaard, E., Kanstrup, I.-L. & Fogh-Andersen, N. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. *Clinical Transplantation* **14**, 457-463, doi:10.1034/j.1399-0012.2000.140503.x (2000).
- 140 Jørgensen, H. S. *et al.* Patterns of renal osteodystrophy 1 year after kidney transplantation. *Nephrology Dialysis Transplantation* **36**, 2130-2139, doi:10.1093/ndt/gfab239 (2021).
- 141 Courbebaisse, M. *et al.* Nonskeletal and skeletal effects of high doses versus low doses of vitamin D(3) in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial. *Am J Transplant* **23**, 366-376, doi:10.1016/j.ajt.2022.12.007 (2023).
- 142 Tsujita, M. *et al.* Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial. *Journal of Bone and Mineral Research* **37**, 303-311, doi:10.1002/jbmr.4469 (2022).
- 143 Courbebaisse, M. *et al.* Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. *Kidney Int* **75**, 646-651, doi:10.1038/ki.2008.549 (2009).
- 144 Wissing, K. M. *et al.* A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. *Transplantation* **79**, 108-115, doi:10.1097/01.tp.0000149322.70295.a5 (2005).
- 145 Talalaj, M. *et al.* Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. *Transplant Proc* **28**, 3485-3487 (1996).
- 146 Courbebaisse, M. *et al.* Nonskeletal and skeletal effects of high doses versus low doses of vitamin D3 in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial. *American Journal of Transplantation*, doi:10.1016/j.ajt.2022.12.007 (2023).

- 147 Pike, J. W., Meyer, M. B., Lee, S. M., Onal, M. & Benkusky, N. A. The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights. *J Clin Invest* **127**, 1146-1154, doi:10.1172/JCI88887 (2017).
- 148 Zhang, R. *et al.* Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response meta-analysis of prospective studies. *Am J Clin Nutr* **105**, 810-819, doi:10.3945/ajcn.116.140392 (2017).
- 149 Herrmann, M. *et al.* The role of functional vitamin D deficiency and low vitamin D reservoirs in relation to cardiovascular health and mortality. *Clin Chem Lab Med*, doi:10.1515/cclm-2024-0391 (2024).
- 150 Zhang, Y. *et al.* Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies. *Nephrol Dial Transplant* **33**, 1742-1751, doi:10.1093/ndt/gfy016 (2018).
- 151 Pilz, S., Iodice, S., Zittermann, A., Grant, W. B. & Gandini, S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. *Am J Kidney Dis* **58**, 374-382, doi:10.1053/j.ajkd.2011.03.020 (2011).
- 152 Duranton, F. *et al.* Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. *Am J Nephrol* **37**, 239-248, doi:10.1159/000346846 (2013).
- 153 Manson, J. E. *et al.* Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *N Engl J Med* **380**, 33-44, doi:10.1056/NEJMoa1809944 (2019).
- 154 Scragg, R. *et al.* Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. *JAMA Cardiol* **2**, 608-616, doi:10.1001/jamacardio.2017.0175 (2017).
- 155 Trivedi, D. P., Doll, R. & Khaw, K. T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* **326**, 469, doi:10.1136/bmj.326.7387.469 (2003).
- 156 Neale, R. E. *et al.* The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. *Lancet Diabetes Endocrinol* **10**, 120-128, doi:10.1016/S2213-8587(21)00345-4 (2022).
- 157 Sutherland, J. P., Zhou, A. & Hypponen, E. Vitamin D Deficiency Increases Mortality Risk in the UK Biobank : A Nonlinear Mendelian Randomization Study. *Ann Intern Med* **175**, 1552-1559, doi:10.7326/M21-3324 (2022).
- 158 Lips, P. *et al.* The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. *J Clin Endocrinol Metab* **67**, 644-650, doi:10.1210/jcem-67-4-644 (1988).
- 159 Limonte, C. P. *et al.* Effects of Vitamin D(3) Supplementation on Cardiovascular and Cancer Outcomes by eGFR in VITAL. *Kidney360* **3**, 2095-2105, doi:10.34067/KID.0006472022 (2022).
- 160 NIHR, N. I. f. H. a. C. R. *Survival Improvement with Cholecalciferol in Patients on Dialysis the SIMPLIFIED registry trial*, <<https://fundingawards.nihr.ac.uk/award/14/49/127>> (
- 161 Levin, A. *et al.* Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD. *Clin J Am Soc Nephrol* **12**, 1447-1460, doi:10.2215/CJN.10791016 (2017).
- 162 Das, S., Selvarajan, S., Kamalanathan, S., Parameswaran, S. & Zachariah, B. A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Efficacy of Oral Cholecalciferol in Improving Renal and Vascular Functions in Vitamin D-Deficient Patients With Type 2 Diabetes Mellitus. *J Diet Suppl* **20**, 44-54, doi:10.1080/19390211.2021.1958041 (2023).
- 163 Samaan, F. *et al.* The Effect of Long-Term Cholecalciferol Supplementation on Vascular Calcification in Chronic Kidney Disease Patients With Hypovitaminosis D. *J Ren Nutr* **29**, 407-415, doi:10.1053/j.jrn.2018.12.002 (2019).
- 164 Banerjee, D. *et al.* Impact of Vitamin D on Cardiac structure and function in CKD patients with hypovitaminosis D, a randomised controlled trial and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*, doi:10.1093/ehjcvp/pvz080 (2019).

- 165 Liyanage, G. C., Lekamwasam, S., Weerarathna, T. P. & Liyanage, C. E. Effects of high-dose parenteral vitamin D therapy on lipid profile and blood pressure in patients with diabetic nephropathy: A randomized double-blind clinical trial. *Diabetes Metab Syndr* **11 Suppl 2**, S767-S770, doi:10.1016/j.dsx.2017.05.013 (2017).
- 166 Krummel, T. *et al.* Effects of high- vs low-dose native vitamin D on albuminuria and the renin-angiotensin-aldosterone system: a randomized pilot study. *Int Urol Nephrol* **54**, 895-905, doi:10.1007/s11255-021-02950-3 (2022).
- 167 Zittermann, A., Berthold, H. K. & Pilz, S. The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. *Eur J Clin Nutr* **75**, 980-987, doi:10.1038/s41430-020-00725-0 (2021).
- 168 Daroux, M. *et al.* Vitamin D2 versus vitamin D3 supplementation in hemodialysis patients: a comparative pilot study. *J Nephrol* **26**, 152-157, doi:10.5301/jn.5000123 (2013).
- 169 Balachandar, R., Pullakhandam, R., Kulkarni, B. & Sachdev, H. S. Relative Efficacy of Vitamin D(2) and Vitamin D(3) in Improving Vitamin D Status: Systematic Review and Meta-Analysis. *Nutrients* **13**, doi:10.3390/nu13103328 (2021).
- 170 van den Heuvel, E. G., Lips, P., Schoonmade, L. J., Lanham-New, S. A. & van Schoor, N. M. Comparison of the Effect of Daily Vitamin D2 and Vitamin D3 Supplementation on Serum 25-Hydroxyvitamin D Concentration (Total 25(OH)D, 25(OH)D2, and 25(OH)D3) and Importance of Body Mass Index: A Systematic Review and Meta-Analysis. *Adv Nutr* **15**, 100133, doi:10.1016/j.advnut.2023.09.016 (2024).
- 171 Tripkovic, L. *et al.* Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr* **95**, 1357-1364, doi:10.3945/ajcn.111.031070 (2012).
- 172 Behairy, M. *et al.* Oral versus intramuscular cholecalciferol replacement in hemodialysis patients with vitamin D deficiency. *Journal of Nephro pharmacology* **11**, e07, doi:10.34172/npj.2022.07 (2022).
- 173 Gupta, N., Farooqui, K. J., Batra, C. M., Marwaha, R. K. & Mithal, A. Effect of oral versus intramuscular Vitamin D replacement in apparently healthy adults with Vitamin D deficiency. *Indian J Endocrinol Metab* **21**, 131-136, doi:10.4103/2230-8210.196007 (2017).
- 174 Tellioglu, A., Basaran, S., Guzel, R. & Seydaoglu, G. Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly. *Maturitas* **72**, 332-338, doi:10.1016/j.maturitas.2012.04.011 (2012).
- 175 Albinsson, E., Gronlund, A. B., Paulsson, M., Wikstrom, S. & Ahlsson, F. Unpredictable supplementation of vitamin D to infants in the neonatal intensive care unit: An experimental study. *Acta Paediatr*, doi:10.1111/apa.17351 (2024).
- 176 Wan, M. *et al.* Quality and use of unlicensed vitamin D preparations in primary care in England: Retrospective review of national prescription data and laboratory analysis. *Br J Clin Pharmacol* **87**, 1338-1346, doi:10.1111/bcp.14521 (2021).
- 177 Garg, S. *et al.* Evaluation of vitamin D medicines and dietary supplements and the physicochemical analysis of selected formulations. *J Nutr Health Aging* **17**, 158-161, doi:10.1007/s12603-012-0090-4 (2013).
- 178 Verkaik-Kloosterman, J., Seves, S. M. & Ocke, M. C. Vitamin D concentrations in fortified foods and dietary supplements intended for infants: Implications for vitamin D intake. *Food Chem* **221**, 629-635, doi:10.1016/j.foodchem.2016.11.128 (2017).
- 179 Khadgawat, R., Ramot, R., Chacko, K. M. & Marwaha, R. K. Disparity in cholecalciferol content of commercial preparations available in India. *Indian J Endocrinol Metab* **17**, 1100-1103, doi:10.4103/2230-8210.122638 (2013).
- 180 LeBlanc, E. S., Perrin, N., Johnson, J. D., Jr., Ballatore, A. & Hillier, T. Over-the-counter and compounded vitamin D: is potency what we expect? *JAMA Intern Med* **173**, 585-586, doi:10.1001/jamainternmed.2013.3812 (2013).
- 181 Nimalaratne, C., Sun, C., Wu, J., Curtis, J. M. & Schieber, A. Quantification of selected fat soluble vitamins and carotenoids in infant formula and dietary supplements using fast liquid

- chromatography coupled with tandem mass spectrometry. *Food Research International* **66**, 69-77, doi:<http://dx.doi.org/10.1016/j.foodres.2014.08.034> (2014).
- 182 Huang, Z. & You, T. Personalise vitamin D(3) using physiologically based pharmacokinetic modelling. *CPT Pharmacometrics Syst Pharmacol* **10**, 723-734, doi:10.1002/psp4.12640 (2021).
- 183 Wan, M. *et al.* Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease. *Br J Clin Pharmacol* **88**, 1223-1234, doi:10.1111/bcp.15064 (2022).
- 184 de Oliveira, L. F., de Azevedo, L. G., da Mota Santana, J., de Sales, L. P. C. & Pereira-Santos, M. Obesity and overweight decreases the effect of vitamin D supplementation in adults: systematic review and meta-analysis of randomized controlled trials. *Rev Endocr Metab Disord* **21**, 67-76, doi:10.1007/s11154-019-09527-7 (2020).
- 185 Shroff, R. *et al.* Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. *J Am Soc Nephrol* **27**, 314-322, doi:10.1681/ASN.2014090947 (2016).
- 186 Aloni, Y., Shany, S. & Chaimovitz, C. Losses of 25-hydroxyvitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis. *Miner Electrolyte Metab* **9**, 82-86 (1983).
- 187 National Kidney, F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* **42**, S1-201 (2003).
- 188 Nadeem, S. *et al.* Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease. *Pediatr Nephrol* **37**, 415-422, doi:10.1007/s00467-021-05228-z (2022).
- 189 Feng, Z. *et al.* Effect of a high vs. standard dose of vitamin D3 supplementation on bone metabolism and kidney function in children with chronic kidney disease. *Front Pediatr* **10**, 990724, doi:10.3389/fped.2022.990724 (2022).
- 190 Nata, N., Kanchanasinith, J., Tasanavipas, P., Supasyndh, O. & Satirapoj, B. Efficacy of Weekly Split versus Single Doses of Ergocalciferol on Serum 25-Hydroxyvitamin D among Patients on Continuous Ambulatory Peritoneal Dialysis: A Randomized Controlled Trial. *Int J Nephrol* **2021**, 5521689, doi:10.1155/2021/5521689 (2021).
- 191 Bischoff-Ferrari, H. A. *et al.* Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. *JAMA Intern Med* **176**, 175-183, doi:10.1001/jamainternmed.2015.7148 (2016).
- 192 Sanders, K. M. *et al.* Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA* **303**, 1815-1822, doi:10.1001/jama.2010.594 (2010).
- 193 Morrone, L. *et al.* Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial. *J Nephrol* **35**, 517-525, doi:10.1007/s40620-021-01104-z (2022).
- 194 Donati, S. *et al.* Calcifediol: Why, When, How Much? *Pharmaceuticals (Basel)* **16**, doi:10.3390/ph16050637 (2023).
- 195 Perez-Castrillon, J. L. *et al.* Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial. *J Bone Miner Res* **36**, 1967-1978, doi:10.1002/jbmr.4387 (2021).
- 196 Cashman, K. D. *et al.* Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. *Am J Clin Nutr* **95**, 1350-1356, doi:10.3945/ajcn.111.031427 (2012).
- 197 Fadda, G. *et al.* Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. *Am J Nephrol* **52**, 798-807, doi:10.1159/000518545 (2021).
- 198 Germain, M. J. *et al.* Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. *BMC Nephrol* **23**, 362, doi:10.1186/s12882-022-02993-3 (2022).
- 199 Sempos, C. T. *et al.* Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. *J Clin Endocrinol Metab* **98**, 3001-3009, doi:10.1210/jc.2013-1333 (2013).

- 200 Durup, D. *et al.* A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. *J Clin Endocrinol Metab* **97**, 2644-2652, doi:10.1210/jc.2012-1176 (2012).
- 201 Durup, D. *et al.* A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. *J Clin Endocrinol Metab* **100**, 2339-2346, doi:10.1210/jc.2014-4551 (2015).
- 202 Zhao, S. *et al.* Associations of serum 25-hydroxyvitamin D and vitamin D receptor polymorphisms with risks of cardiovascular disease and mortality among patients with chronic kidney disease: a prospective study. *Am J Clin Nutr*, doi:10.1016/j.ajcnut.2024.04.001 (2024).
- 203 Tantiyavarong, P. *et al.* Changes in clinical indicators related to the transition from dialysis to kidney transplantation-data from the ERA-EDTA Registry. *Clinical Kidney Journal* **13**, 188-198, doi:10.1093/ckj/sfz062 (2019).
- 204 Rolighed, L. *et al.* Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. *J Clin Endocrinol Metab* **99**, 1072-1080, doi:10.1210/jc.2013-3978 (2014).
- 205 Holick, M. F. *et al.* Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **96**, 1911-1930, doi:10.1210/jc.2011-0385 (2011).
- 206 Lips, P. *et al.* Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *Eur J Endocrinol* **180**, P23-P54, doi:10.1530/EJE-18-0736 (2019).
- 207 Kaur, J., Khosla, S. & Farr, J. N. Effects of diabetes on osteocytes. *Curr Opin Endocrinol Diabetes Obes* **29**, 310-317, doi:10.1097/MED.0000000000000733 (2022).
- 208 Liyanage, P., Lekamwasam, S., Weerathna, T. P. & Liyanage, C. Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial. *J Postgrad Med* **64**, 10-15, doi:10.4103/jpgm.JPGM_598_16 (2018).
- 209 Nata, N., Siricheepchaiyan, W., Supasyndh, O. & Satirapoj, B. Efficacy of high versus conventional dose of ergocalciferol supplementation on serum 25-hydroxyvitamin D and interleukin-6 levels among hemodialysis patients with vitamin D deficiency: A multicenter, randomized, controlled study. *Ther Apher Dial* **26**, 378-386, doi:10.1111/1744-9987.13722 (2022).
- 210 Mager, D. R., Jackson, S. T., Hoffmann, M. R., Jindal, K. & Senior, P. A. Vitamin D(3) supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial. *Clin Nutr* **36**, 686-696, doi:10.1016/j.clnu.2016.05.012 (2017).

Tables + table legends:

Table 1 Definitions of vitamin D deficiency and adequacy according to different organisations (divide by 2.5 to convert from nmol/L to ng/mL)

Agency	Deficiency threshold nmol/L	Adequacy threshold nmol/L
European Food Safety Authority [§]	<30	>50
Nordic co-operation*	<30	>50
Institute of Medicine ^{&}	<30	>50
Endocrine Society ²⁰⁵	<50	>75
European Calcified Tissue Society ²⁰⁶	<50	

[§] Dietary reference values for vitamin D. 4547 (European Food Safety Authority, 2016).

* Nordic nutrition recommendations 2012: integrating nutrition and physical activity. (Nordic Council of Ministers, Copenhagen, 2012).

[&] Dietary reference intakes for calcium and vitamin D. (Institute of Medicine, Washington, D.C., 2010).

ORIGINAL UNEDITED MANUSCRIPT

Table 2: Randomized trials of vitamin D supplementation on parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD) (divide by 2.5 to convert from nmol/l to ng/ml)

Study	N	Population, CKD grade	Supplement and dose	Equivalent daily dose	Duration	Baseline 25(OH)D (nmol/L)	Follow-up 25(OH)D (nmol/L)	PTH change
Dogan 2008 ¹⁰¹	70	Adults, G3-4	Chol 300000IU/mo vs none	10000	12 wks	21/17	45/18	↓
Chandra 2008 ¹⁰²	34	Adults, G3-4	Chol 50000 IU/wk vs placebo	7143	12 wks	43/47	123/49	—
Alvarez 2012 ⁹⁴	46	Adults, G2-3	Chol 50000 IU/wk for 12 wks > 50000 IU/2 wk for 40 wks vs placebo	7143 then 3572	52 wks	67/80	107/66	↓
Marckmann 2012 ⁹⁷	27	Adults, G1-5D	Chol 40000 IU/wk vs placebo	5715	8 wks	39/29	166/22	↓
Petchey 2013 ⁹⁶	28	Adults, G3-4	Chol 2000 IU/d vs placebo	2000	24 wks	95/88	146/81	—
Kumar 2017 ¹⁰⁰ and Yadav 2018 ⁹⁹	120	Adults, G3-4	Chol 300000 IU every 8 wks vs placebo	5357	16 wks	33/33	95/37	↓
Westerberg 2018 ⁹⁸	95	Adults, G3-4	Chol 8000 IU/d vs placebo	8000	12 wks	58/57	162/57	↓
Shroff 2012 ¹²²	47	Children, G2-4	Ergo 2-8000IU/d for 3mo, then 2000IU/d for 9mo vs placebo	2-8000 then 2000	52 wks	50/52	83/	↓
Gravesen 2013 ⁹⁵	43	Adults, G4-5	Ergo 50000 IU/wk vs none	7143	8 wks	63/59	129/60	—
Dreyer 2014 ¹¹⁴	38	Adults, G3-4	Ergo 50000 IU/wk for 1 mo then 50000 IU/mo vs placebo	7143, then 1667	24 wks	30/25	80/25	—
Sprague 2014 ¹¹⁹	78	Adults, G2-4	Calcifediol (ERC) 30, 60 or 90 µg vs placebo	—	6 wks	55/50	93-212/46	↓
Sprague 2016 ¹¹⁸	213 216	Adults, G3-4	Calcifediol (ERC) 30 or 60 µg vs placebo	—	26 wks + 26 wks open-label extension	50/50	125-172/50	↓

Abbreviations: HD=haemodialysis; PD=peritoneal dialysis; PTH=parathyroid hormone

Table 3: Randomized trials of vitamin D supplementation on parathyroid hormone (PTH) levels in adults with kidney failure (divide by 2.5 to convert from nmol/L to ng/mL)

Study	N	CKD grade	Supplement and dose	Equivalent daily dose (IU/d)	Duration	Baseline 25(OH)D (nmol/L)	Follow-up 25(OH)D (nmol/L)	PTH change
Marckmann 2012 ⁹⁷	25	G1-5D (HD)	Chol 40000 IU/wk vs placebo	5715	8 wks	21/36	136/26	—/↓*
Delanaye 2013 ¹¹³	43	G5D (HD)	Chol 25000 IU/2wks vs placebo	1786	52 wks	30/30	80/44	↓
Hewitt 2013 ¹¹²	60	G5D (HD)	Chol 50000 IU/wk for 8 wks then /mo vs placebo	7143 then 1667	24 wks	43/43	88/40	—
Li 2014 ¹¹¹	96	G5D (HD)	Chol 50000 IU/wk for 6 wks then 10000 IU/wk vs none	7143 then 1429	52 wks	34/33	106/40	—
Massart 2014 ¹¹⁰	55	G5D (HD)	Chol 25000 IU/wk vs placebo	3571	24 wks	46/43	88/41	—
Bhan 2015 ¹¹⁵	105	G5D (HD)	Ergo 50000 IU /wk or /mo vs placebo	7143 or 1667	16 wks	55/56/54	125 or 96 /69	—
Zheng 2016 ¹⁰⁸	60	G5D (HD)	Chol 5000 IU/wk vs none	714	16 wks	49/49	76/49	↓
Wang 2016 ¹⁰⁹	746	G5D	Chol 50000 IU/wk vs placebo	7143	52 wks	55/58	103/58	↓
Zheng 2018 ¹⁰⁷	60	G5D (HD)	Chol 5000 IU/d vs none	5000	24 wks	46/48	94/58	↓
Alshahawey 2021 ¹⁰⁶	60	G5D (HD)	Chol 200000 IU/mo vs placebo	6667	12 wks	45/47	80/47	↓
Matuszkiewicz-Rowinska 2022 ¹⁰⁴	62	G5D (HD)	Chol 4000 IU x3/wk vs alfacalcidol or placebo	1714	12 wks	32/38	78/33	—
Brimble 2022 ¹⁰⁵	65	G5D (PD)	Chol 50000 IU/wk for 8 wks then 10000 IU/wk vs placebo	7143 then 1429	52 wks	52/49	69/40	—

Abbreviations: Chol=Cholecalciferol; Ergo=Ergocalciferol; HD=haemodialysis; PD=peritoneal dialysis; PTH=parathyroid hormone, *Prevalence of hyperparathyroidism decreased with cholecalciferol.

All studies included adult patients; no trials with children in CKD G5D were identified.

Table 4: Randomized controlled trials of vitamin D supplementation after kidney transplantation with bone or biochemical outcomes (divide by 2.5 to convert from nmol/L to ng/mL)

Study	N	Population	Intervention	Duration	Equivalent daily dose (IU/d)	Baseline 25(OH)D (nmol/L)	Follow-up 25(OH)D (nmol/L)	PTH	BMD	Fracture
Courbebaisse 2023 ¹⁴⁶	536	Prevalent, 12-48 mo post-TX	Chol 100000 IU (<i>high</i>) vs 12000 IU (<i>low</i>) every 2 wks for 2 mo, then /mo	24 mo	7143 then 3333 vs 857 then 400	51/48	108/63	↓	No effect (LS, FN)	Reduced risk (clinical fractures)
Tsjuita 2022 ¹⁴²	193	Incident, 1 mo post-TX	Chol 4000 IU/d vs placebo	12 mo	4000	25/25	100/35	↓	Improved (LS)	Not reported
Courbebaisse 2009 ¹⁴³	94	Incident, 3 mo post-TX	Chol 100000 IU /2 wks for 2 mo followed by every 2 mo vs none	12 mo	7143 then 1667	35/30	75/32	↓	Not reported	Not reported
Wissing 2005 ¹⁴⁴	90	Incident, from TX	Chol 25000 IU/mo with 400 mg/d Ca vs Ca alone	12 mo	822	61/49	67/41	↓	No effect (LS, FN)	Not reported
Talalaj 1996 ¹⁴⁵	71	Incident, from TX	Calcidiol 40 µg/d + Ca 3 g/d vs none	12 mo	1600	32/41	72/48	–	Improved (LS, FN)	Reduced risk (incident VFx)

Data are mean ± SD or median [IQR], * marks full range – as given in the source data.

Abbreviations: BMD=bone mineral density; Ca=calcium; Calc=calcidiol; Chol=Cholecalciferol; FN=Femoral neck; LS=lumbar spine; N/A = Not available; VFx=Vertebral fracture; TX=transplantation

ORIGINAL UNEDITED MANUSCRIPT

Table 5: Randomized trials investigating the effect of nutritional vitamin D supplementation on intermediate cardiovascular endpoints in patients with chronic kidney disease (CKD) (divide by 2.5 to convert from nmol/L to ng/mL)

Study	N	CKD grade	Supplement and dose	Equivalent daily dose (IU/day)	Duration	Baseline 25(OH)D (nmol/L)	Follow-up 25(OH)D (nmol/L)	Effect on cardiovascular outcome
Alvarez 2012 ⁹⁴	46	G2-3	Chol 50000 IU /wk for 12 wks, then /2 wks vs placebo	7143 then 3572	52 wks	67/67	100/80	Blood pressure: —
Courbebaisse 2023 ¹⁴¹	53 6	G1-5T	Chol 100000 IU vs 12000 IU both /2 wks for 2 mo, then /mo	7143 then 3333 vs 857 then 400	104 wks	50/50	107/62	MACE: —
Levin 2017 ¹⁶¹	87	G3b-4	Calcifediol 5000 3x/wk vs placebo	2143	26 wks	67/67	235/65	PWV: —/↓
Banerjee 2021 ¹⁶⁴	48	G3-4	Chol 100000 IU at wk 0, 4, 8, 12, 24, 42 vs placebo	1648	52 wks	46/37	~75/~40	LVMI: —
Das 2023 ¹⁶²	10 0	G3	Chol 3000 IU/wk for 8 wks vs placebo	429	24 wks	42/42	90/60	PWV: —
Dreyer 2014 ¹¹⁴	38	G3-4	Ergo 50000/wk for 1 mo, then /mo vs placebo	7143, then 1,667	26 wks	30/25	80/25	Endothelial function: ↑
Hewitt 2013 ¹¹²	66	G5D(HD)	Chol 50000/wk for 8 wks, then/mo vs placebo	7143 then 1,667	26 wks	45/40	88/40	PWV: —
Kumar 2017 ¹⁰⁰ & Kaur 2022 ²⁰⁷	12 0	G3-4	Chol 300000 wk 0 and 8 vs placebo	5357	16 wks	32/32	94/34	FMD: ↑; PWV: ↓
Liyanage 2017 ¹⁶⁵ & 2018 ²⁰⁸	85	G1-3	Chol 50000 im/mo vs placebo	1667	52 wks	55/50	82/46	Blood pressure: —
Marckmann 2012 ⁹⁷	52	G1-5D	Chol 40000/wk vs placebo	5715	8 wks	24/33	155/24	Blood pressure, PWV: —
Massart 2014 ¹¹⁰	55	G5D(HD)	Chol 25000/wk vs placebo for 13 wks, then 26 wks to target	3571 (individualized)	39 wks	42/45	65/65	Aortic calcification: —
Samaan 2018 ¹⁶³	47	G3-4	Chol 50000/mo vs placebo	1667	78 wks	50/55	95/75	Coronary artery calcification score: —

Abbreviations: Chol=Cholecalciferol, Ergo=Ergocalciferol, HD=haemodialysis, MACE=major cardiovascular events, PWV=Pulse wave velocity, FMD=flow mediated vasodilatation, LVMI=left ventricular mass index

All studies included adult patients with CKD; no studies with children were identified

Table 6: Randomised trials comparing different types of nutritional vitamin D in adults with chronic kidney disease (divide by 2.5 to convert from nmol/L to ng/mL)

Study	N	CKD stage	Baseline 25(OH)D (nmol/l)	Ergocalciferol dose	Cholecalciferol dose	Outcome
Wetmore 2016 ¹⁰³	44	G3-5	Ergo: 51 Chol: 52	50000 IU /wk for 12 wks	50000 IU /wk for 12 wks	Cholecalciferol yielded a greater mean change in 25(OH)D (113 ± 41 nmol/l) than ergocalciferol (77 ± 38 nmol/l) and was more efficient in decreasing PTH.
Daroux 2013 ¹⁶⁸	39	G5D (HD)	50	200000 IU /mo given as 3x week, or /mo for 3 mo	200000 IU /mo for 3 mo	Cholecalciferol yielded a greater mean change in 25(OH)D (100 ± 33 nmol/l) than ergocalciferol (63 ± 23 nmol/l).

Abbreviations: 25(OH)D = 25-hydroxyvitamin-D; Chol=Cholecalciferol; Ergo=Ergocalciferol; HD = Haemodialysis; IU = International unit; PTH = Parathyroid hormone

Table 7: Randomised trials of nutritional vitamin D comparing different dosing intervals in patients with chronic kidney disease

Study	N	Population	CKD Stage	Vitamin D compound	Route	Intervention	Follow-up	Outcome
Iyengar 2022 ¹²⁹	90	Children <18 yrs	G3-4	Chol	Oral	3000 IU /d or 25000 IU /wk or 100000 IU /mo for 3 mo	3 mo	Similar effects on 25(OH)D
Nata 2022 ²⁰⁹	50	Adults ≥ 18 yrs	G5D (PD)	Ergo	Oral	20000 IU 3x /wk or 60000 IU /wk for 8 wks	8 wks	Similar effects on 25(OH)D

Abbreviations: 25(OH)D = 25-hydroxyvitamin-D; Chol=Cholecalciferol; Ergo=Ergocalciferol; PD = Peritoneal dialysis; IU = International unit

ORIGINAL UNEDITED MANUSCRIPT


Table 8: Randomised, controlled trials investigating oral calcifediol in adults with chronic kidney disease (CKD) (divide by 2.5 to convert from nmol/L to ng/mL)

Study	n	CKD stage	Supplement and dose	Follow-up	Baseline 25(OH)D (nmol/L)	Follow-up 25(OH)D (nmol/L)	Outcome
Morrone 2022 ¹⁹³	284	G5D (HD)	Calcifediol 40 µg x3/wk vs none	24 mo	30/32	Not given	A greater proportion of patients achieved 25(OH)D>75 nmol/L: 36 vs 11%. No significant effects on mortality or cardiovascular outcomes.
Levin 2017 ¹⁶¹	80	G3-4	Calcifediol 5000 IU x3/wk vs placebo	6 mo	63/74	235/65	Mean 25(OH)D change in the calcifediol group was 171 (145; 197) nmol/l. Pulse wave velocity decreased compared to placebo-group.
Sprague 2016 ¹¹⁸ & Strugnell 2019 ¹²¹	144 + 285	G3-4	ERC 30–60 µg/d vs placebo	26 wks	50/50	125-172/50	Steady-state 25(OH)D was reached after 12 wks and averaged 125 and 140 nmol/l (30 µg/d) and 173 and 168 nmol/l (60 µg/d). Target 25(OH)D (>75 nmol/L) was achieved in 80 and 83% vs 3 and 7% (active vs placebo).
Sprague 2014 ¹¹⁹	78	G3-4	ERC 30, 60, or 90 µg/d vs placebo	6 wks	55/50	93-212/46	Mean 25(OH)D increased to 93±5 nmol/l (30 µg/d), 167 ± 44 nmol/l (60 µg/d) and 212 ± 14 nmol/l (90 µg/d). Target 25(OH)D (>75 nmol/L) was achieved in 90 vs 3% (active vs placebo).
Strugnell 2023 ¹²⁰	69	G3-4	ERC 60 µg/d vs IRC 266 µg/mo vs CHL 300000 IU/mo vs PAR 1-2 µg +CHL 800 IU/d	8 wks	52	ERC 207 /IRC 63 /CHL 72 /PAR 60	Target 25(OH)D (>75 nmol/L) was achieved in 100% (ERC), 27% (IRC), 44% (high-dose CHL) and 15% (PAR)

25(OH)D = 25-hydroxyvitamin-D; ERC=extended release; IRC=intermediate release; IU = International unit; PAR=paricalcitol; PTH = Parathyroid hormone

Figures + figure legends:

Figure 1. Overview of vitamin D metabolism. Vitamin D is supplied through ultraviolet radiation of the skin or through the diet. Two hydroxylation steps are necessary for activation into the active hormone, first by CYP2R1 in the liver to 25 hydroxyvitamin D (25(OH)D) then in by CYP27B1 in the kidneys or other tissues to 1,25 dihydroxy vitamin D (1,25(OH)₂D). Hepatic hydroxylation may be affected by energy metabolism, with reduced efficacy seen in diabetes mellitus and obesity. Renal CYP27B1 is under strict hormonal control by hormones governing mineral metabolism (parathyroid hormone, PTH and fibroblast growth factor 23, FGF23), with negative feedback from 1,25(OH)₂D itself. In contrast, extrarenal CYP27B1 activity seems to be substrate dependent and stimulated by conditions of inflammation.




Created with BioRender.com

ORIGINAL


SCRIPT

Figure 2. Renal vitamin D metabolism and primary regulators of 1α -hydroxylase and 24-hydroxylase enzymes. Vitamin D metabolites circulate bound to proteins, mainly vitamin D protein. The 25-hydroxyvitamin D-DBP complex enters the proximal tubular cells from the glomerular filtrate through a megalin/cubulin mediated transport. 1α -hydroxylase (encoded by CYP27B1) is a cytochrome P450 enzyme that catalyzes the hydroxylation of 25-hydroxyvitamin D (25[OH]D) to 1,25-dihydroxyvitamin D (1,25[OH]₂D; the active form of vitamin D). 24-hydroxylase (encoded by CYP24A1) catalyzes the 24-hydroxylation of 25(OH)D and 1,25(OH)₂D to their inactive 24-metabolites. Factors that regulate each enzyme are depicted in the figure. Renally produced 1,25[OH]₂D serves autocrine (genomic and non-genomic), paracrine and endocrine functions. Abbreviations: 24,25(OH)₂D, 24,25-dihydroxyvitamin D; FGF23, fibroblast growth factor 23; PTH, parathyroid hormone; DBP, Vitamin D binding protein; Ca, calcium; Phos, Phosphate; VDRE, vitamin D responsive element; VDR, vitamin D receptor; RXR, retinoid X receptor




Created with Biorender.com

Figure 3. Extrarenal vitamin D metabolism and primary regulators of 1α -hydroxylase and 24 -hydroxylase enzymes. Free circulating 25 -hydroxyvitamin D enters the cells through diffusion. Factors that regulate extrarenal CYP27B1 and CYP24A1 are depicted in the figure. Extrarenally produced $1,25(\text{OH})_2\text{D}$ mainly serves autocrine (genomic and non-genomic) and paracrine functions, but may also spill over the circulation and thus confer endocrine actions. Abbreviations: $24,25(\text{OH})_2\text{D}$, $24,25$ -dihydroxyvitamin D; FGF23, fibroblast growth factor 23; PTH, parathyroid hormone; DBP, Vitamin D binding protein; VDRE, vitamin D responsive element; VDR, vitamin D receptor; RXR, retinoid X receptor



Created with Biorender.com


Figure 4. Association between predicted levels of 25(OH)D, based on genetic determinants, and all-cause and cause-specific mortality; arrows indicate the median baseline level in the VITamin D and Omega-3 Trial (VITAL)¹⁵³. CV=Cardiovascular (divide by 2.5 to convert from nmol/L to ng/mL)



LPT

ORIGINAL UNEDITED


Figure 5. 25(OH)D response of 16 study arms from randomised controlled trials of nutritional vitamin D in adults with CKD where the outcome was change in PTH levels (divide by 2.5 to convert from nmol/L to ng/mL). Studies included: Alvarez et al., 2012⁹⁴; Marckmann et al. 2012⁹⁷; Westerberg et al., 2018⁹⁸; Yadav et al., 2018⁹⁹; Kumar et al., 2017¹⁰⁰; Dogan et al., 2008¹⁰¹; Chandra et al., 2008¹⁰²; Matuszkiewicz-Rowinska et al., 2021¹⁰⁴; Alshahawey et al., 2021¹⁰⁶; Zheng et al., 2018¹⁰⁷; Zheng et al., 2016¹⁰⁸; Massart et al., 2014¹¹⁰; Li et al., 2014¹¹¹; Hewitt et al., 2013¹¹²; Delanaye et al., 2013¹¹³.



ORIGINAL UNEDITED

-RIPT

Figure 6. 25(OH)D response of 5 study arms from randomised controlled trials of nutritional vitamin D in adults with CKD where doses to maintain 25(OH)D levels were investigated (divide by 2.5 to convert from nmol/L to ng/mL). Data for the initial period where higher doses of vitamin D were used in some of these studies are excluded for illustration purposes only. Studies included: Alvarez et al., 2012⁹⁴; Li et al., 2014¹¹¹; Hewitt et al., 2013¹¹²; Mager et al., 201²¹⁰. (Note: Mager et al., 2016 included patients with CKD G1-2).



ORIGINAL UNEDITED